| OpenEvidence |
Treat as clinician-facing medical information and clinical reference support unless a deployment uses it for patient-specific clinical decision support that changes regulatory obligations. |
Check user eligibility, PHI-entry policy, HIPAA-aligned processing claims, retention, sponsorship or network-profile terms, and whether organization-level agreements are available. |
Verify every answer against the displayed citations and confirm which licensed journals, guidelines, or source partnerships are available for the clinical question. |
Best governed as fast evidence lookup for verified clinicians, with local rules for patient-specific prompts, citation review, and documentation of decisions made outside the tool. |
| ClinicalKey AI |
Treat as clinician-facing clinical reference and decision-support software; verify whether local use remains non-device CDS or creates regulated obligations because patient context and clinical recommendations may be involved. |
Review HIPAA-compliant claims, encryption, query history, pseudonymized support access, institutional license terms, and whether prompts or patient details are shared with model or cloud partners. |
Confirm the answer cites current licensed content that actually supports the claim, and sample high-risk specialty questions before trusting it in point-of-care workflows. |
Best governed as a clinician-reviewed evidence lookup layer with local rules for patient-specific prompts, citation checking, flagged answers, and documentation outside the product. |
| UpToDate Expert AI |
Treat as high-risk clinician-facing clinical decision support; confirm whether the exact use remains reference support or becomes regulated patient-specific CDS in the deployment setting. |
Review UpToDate terms before entering patient context, because public terms restrict personal data and PHI for Expert AI; enterprise agreements may differ and should be checked directly. |
Validate that each answer links to current UpToDate topics that support the recommendation, and sample complex specialty cases for assumptions, omissions, and hallucination handling. |
Best governed as a clinician-reviewed UpToDate search layer with local rules for PHI, source checking, documentation, escalation, and when to consult primary guidelines or specialists. |
| Dyna AI |
Treat as high-risk clinical decision-support retrieval rather than autonomous care; review whether local use remains clinician reference support and how DynaMed Decisions or shared-decision tools are separated. |
Check institutional contract terms, because public AI terms prohibit HIPAA-protected or similar medical data input into AI tools and place responsibility for output review on the user. |
Verify answers against DynaMed, DynaMedex, or Dynamic Health source links, update timestamps, and specialty coverage before using output in point-of-care decisions. |
Best governed as a switchable AI/search mode inside existing EBSCO clinical content workflows, with clinician review, source checking, query reruns, and documentation outside the tool. |
| Glass Health |
Treat differential diagnosis, treatment planning, triage, ambient insights, and encounter-specific recommendations as high-risk CDS; map every deployed function against FDA non-device CDS criteria, intended use, explainability, clinician independence, and any local medical-device obligations. |
Review individual versus clinic or enterprise terms, BAA availability, prompts and outputs, audio and transcripts, EHR context, API payloads, payment data, support access, retention, de-identified or aggregated data, and whether service-improvement or model-training rights fit the deployment. |
Require citation review, guideline currency checks, local chart audits, ambient transcript accuracy testing, drug-information verification, subgroup review, and clinician override tracking before using Glass outputs in patient-specific decisions. |
Best governed as clinician-reviewed reasoning and documentation support with clear rules for when outputs may enter notes, orders, referrals, discharge instructions, patient handouts, or software workflows. |
| Consensus |
Treat as research and education support, not clinical decision support or a diagnostic system. |
Avoid entering patient-identifiable information unless contract and privacy terms explicitly support the use case. |
Verify database coverage, study filters, Consensus Meter interpretation, and whether each cited paper supports the generated answer. |
Best for literature discovery, study triage, and student or writer workflows where users manually review the underlying papers. |
| Elicit |
Treat as literature-review and evidence-synthesis workflow software rather than patient-care decision support. |
Use de-identified literature and project materials unless enterprise terms explicitly cover confidential or patient-related documents. |
Validate search recall, screening decisions, extraction fields, source quotes, and PRISMA-style audit trail on the review topic before relying on outputs. |
Best for systematic-review teams that keep human reviewer reconciliation, protocol documentation, and final appraisal outside the automation. |
| Scite |
Treat as research support and citation-context analysis, not clinical decision support. |
Avoid uploading PHI or confidential manuscripts unless the subscription and privacy terms cover that workflow. |
Check coverage for the specialty, how citation statements are classified, and whether assistant summaries match the cited source context. |
Best for claim checking, literature mapping, and manuscript review where humans still appraise study quality and clinical relevance. |
| Atropos Health |
Treat as high-governance evidence generation and clinical-reference support; verify whether local use affects care decisions enough to trigger CDS, IRB, data-use, or policy review. |
Confirm whether questions use local EHR data, federated network data, or de-identified inputs, then review data-use agreements, PHI handling, and Microsoft or EHR integration terms. |
Require methods transparency for each real-world evidence report, including cohort definition, source network, statistical approach, uncertainty, and literature support. |
Best for health systems and life-sciences teams that can route outputs through clinician, methods, data-governance, or medical-affairs review before action. |
| Doximity Ask |
Treat as clinician workflow support unless a local deployment uses it for regulated clinical decision support; verify intended-use claims before point-of-care reliance. |
Doximity states HIPAA-compliant protocols, PHI support, and encryption in transit and at rest; confirm contract, retention, audit, and enterprise controls for organization use. |
Support materials say responses can use referenced evidence and preferred journals; clinicians still need to check sources and hallucination warnings. |
Best evaluated as a clinician-authenticated assistant for first drafts, education, translation, document review, and clinical reference inside Doximity. |
| Medwise AI |
Treat as clinical information and research support rather than a regulated medical device based on the public terms, but review any local deployment that uses patient context, uploaded files, or care-pathway decisions. |
Review the terms and privacy notice before entering patient context because public terms restrict personal, confidential, privileged, proprietary, or sensitive uploads and the app separately warns against identifiable medical-image and PII uploads. |
Require clinicians to open and verify the displayed source passages, UK SPCs, local guidance, literature, and no-answer behavior before relying on a generated summary. |
Best governed as a clinician-reviewed lookup layer for UK practice, with local rules for prompt content, uploaded files, recordings, source checking, and documentation outside the tool. |
| AvoMD |
Treat as clinical decision support whose risk depends on the pathway, calculator, automation, and intended use; verify whether any local workflow needs FDA, SaMD, or institutional CDS review. |
Review PHI flow through EHR integration, prompts, analytics, user access, retention, vendor subprocessors, BAA terms, and security documentation before enabling patient-context workflows. |
Require current guideline sources, local approver records, logic transparency, test cases, and monitoring for outdated or unsafe pathway behavior. |
Best deployed through a clinical governance process with named pathway owners, version control, clinician override paths, and staged rollout monitoring. |
| VisualDx |
Treat as clinician-reviewed clinical decision support and dermatology image-analysis support; confirm whether the selected function is non-device CDS, educational reference, or a regulated workflow in the deployment jurisdiction. |
Review institutional privacy and security terms before uploading patient photos or using mobile image analysis, including consent, retention, account access, API use, and whether an enterprise agreement or BAA is required. |
Validate performance and usability with local clinicians across skin tones, ages, body locations, common mimics, rare diagnoses, and referral thresholds rather than relying on image-search convenience alone. |
Best governed as supervised differential support with clinician confirmation, source review, documentation outside the tool, escalation rules for dangerous rashes, and clear patient-education boundaries. |
| Isabel DDx Companion |
Treat as high-risk clinician-facing diagnostic decision support; verify local SaMD, CDS, EHR integration, and institutional review requirements before relying on patient-specific outputs. |
Review PHI entry, EMR extraction, API data flow, hosted service terms, access controls, audit logs, BAA or DPA coverage, and retention before using real patient records. |
Validate top-differential behavior, red-flag coverage, rare-disease handling, evidence links, drug-related symptom suggestions, and false reassurance risk against local cases and clinician review. |
Best governed as a differential broadening and teaching aid with accountable clinician review, documentation outside the tool, escalation rules, and monitoring for missed or over-weighted diagnoses. |
| Causaly |
Treat as biomedical research and R&D decision-support infrastructure unless a deployment supports regulated submissions or care decisions; then require study-specific validation, audit, and compliance review. |
Review enterprise terms for internal documents, private data, third-party data, AI-agent access, retention, customer IP, and any patient-derived or confidential dataset before deployment. |
Validate factual grounding, source traceability, graph provenance, no-answer behavior, and expert-review requirements for each target assessment, indication search, or regulatory-evidence workflow. |
Best governed as a repeatable scientific research workspace with named reviewers, versioned evidence packages, documented assumptions, and escalation for uncertain or unsupported conclusions. |
| AMBOSS AI Mode |
Treat as clinical reference, medical education, and evidence-navigation support unless a local deployment uses patient-specific context in a way that triggers clinical decision-support or medical-device governance. |
Review AMBOSS privacy, institutional-license terms, prompt policies, upload handling, account data, retention, processor roles, and whether PHI or identifiable patient context is permitted before clinical use. |
Require users to open the linked AMBOSS articles, guidelines, drug references, and selected external sources because AI Mode is still an evidence-navigation layer that needs human verification. |
Best governed as a source-backed lookup and learning assistant with explicit rules for clinical use, student assignments, patient-specific prompts, source checking, and documentation outside the tool. |
| Abridge |
Position it as clinician documentation support unless a local workflow extends it into coding, prior authorization, or other regulated decision support that needs separate review. |
Review the contract path for BAA terms, recording consent, retention, training-data use, and security documentation from the trust center before piloting with PHI. |
Pilot with specialty-specific encounters and measure missing facts, hallucinated text, source-to-note provenance, and clinician edit burden. |
Best evaluated where note provenance, clinician review, and direct EHR insertion are required inside enterprise documentation workflows. |
| Ambience Healthcare |
Treat it primarily as documentation and revenue-support workflow software unless local use expands into clinical guidance or order support that changes the review burden. |
Confirm how PHI is processed under customer agreements, whether a BAA applies, and how recordings, transcripts, and downstream chart data are retained and secured. |
Validate specialty-specific documentation, coding, and CDI performance on real encounters before expanding beyond a controlled pilot. |
Most relevant for organizations that want one vendor spanning chart prep, ambient capture, note generation, and post-visit documentation tasks inside supported EHR workflows. |
| Nuance DAX Copilot |
Treat it as documentation support rather than autonomous clinical decision support unless a connected workflow adds higher-risk reasoning or coding automation. |
Review Azure-hosting, recording, retention, HITRUST/security documentation, and the exact Microsoft or Nuance contract path for PHI handling and business-associate terms. |
Measure documentation quality, specialty fit, review burden, and any vendor-published productivity claims against your own clinician pilot. |
Best suited to organizations already aligned with Dragon, Microsoft Cloud for Healthcare, and supported EHR insertion workflows. |
| Microsoft Dragon Copilot |
Treat documentation as lower-to-medium risk, but review radiology reporting, coding suggestions, order capture, and decision-support features separately because each can change regulatory and clinical accountability. |
Review Microsoft healthcare contract terms, Azure/security documentation, recording and transcript retention, EHR integration permissions, third-party reference content, and business-associate coverage before PHI use. |
Validate Dragon Copilot's output against real specialty encounters, radiology reports, nurse flowsheet workflows, and cited medical references instead of relying on broad productivity claims. |
Best governed as a role-specific clinical workspace with local configuration, clinician review, EHR insertion checks, and separate approval for automation beyond note drafting. |
| Oracle Health Clinical AI Agent |
Treat chart review and care-related summaries as higher-risk clinical decision support because outputs use patient-specific EHR data; planned administrative or patient-facing features need separate intended-use review. |
Review Oracle Health security materials, EHR access permissions, audit logging, incident reporting, data residency, and contract terms before enabling patient-specific workflows. |
Validate source links, summary completeness, missed data, hallucinated facts, and workflow-specific recommendations against representative charts before clinicians rely on outputs. |
Best governed as an embedded EHR agent with role-based permissions, source review, clinician judgment, exception escalation, and clear separation between live and planned functionality. |
| AWS HealthScribe |
Treat it as documentation infrastructure for draft notes; review the finished application, specialty scope, EHR insertion, and any clinical-decision or coding extensions separately. |
Design PHI controls across the full AWS workflow, including BAA eligibility, S3 storage, customer-managed keys, IAM, retention, logging, application databases, and downstream EHR integrations. |
Use transcript evidence mapping during pilots and measure factual completeness, factual correctness, speaker attribution, omitted observations, hallucinated text, and performance under noisy or complex encounters. |
Best governed as a builder platform with explicit clinician review, correction capture, exception handling for unsupported visits, and monitoring for audio-quality and specialty-specific failure modes. |
| DeepScribe |
Treat core scribing as clinician-reviewed documentation support, but evaluate diagnosis-intelligence, pre-chart synthesis, E/M, ICD-10, HCC, and revenue-integrity features separately because they may affect clinical or billing decisions. |
Review BAA terms, recording consent, audio and transcript retention, de-identification, EHR permissions, mobile or desktop capture, SSO/MFA setup, support access, security documentation, and whether customer data is used for model improvement. |
Validate note completeness, hallucinated or omitted details, source-chart summary accuracy, coding-support rationale, specialty terminology, language support, and clinician edit burden against representative encounters before expansion. |
Best governed as an ambient documentation workflow with explicit patient notice, clinician review and signoff, EHR insertion checks, exception handling for unsupported visits, and separate oversight for coding or diagnosis-surfacing outputs. |
| Suki |
Treat it as clinician workflow support unless a local deployment leans on reasoning or coding features as unsupervised clinical decision support. |
Review HIPAA, security, BAA, recording-consent, and webhook or integration controls for the exact deployment model you plan to use. |
Pilot documentation quality, coding assistance, and any Q&A features separately because each workflow carries a different verification burden. |
Most useful where voice-enabled documentation, edits, and EHR-connected assistant actions need to fit into clinician-controlled workflows. |
| Nabla |
Use it as clinician documentation support unless your deployment expands into higher-risk clinical reasoning or patient-specific decision support. |
Verify no-audio-storage defaults, feedback-data handling, chosen hosting region, BAA or regional privacy terms, and the exact scope of security certifications. |
Pilot on specialty language, multiple speakers, accents, and complex visits instead of assuming general scribe performance transfers to your setting. |
Best for teams comparing lighter-weight scribe adoption against enterprise governance requirements and supported EHR integrations. |
| Freed |
Treat it as draft documentation support, not autonomous clinical documentation or coding submission. |
Confirm HIPAA or BAA terms, audio-retention settings, account controls, and whether the planned workflow fits local privacy policy before entering PHI. |
Use a small pilot to measure note completeness, specialty fit, and clinician correction burden instead of assuming consumer-like ease means clinical readiness. |
Best for individual clinicians or smaller practices that need a simpler scribe workflow before evaluating heavier enterprise integrations. |
| Heidi Health |
Separate documentation, evidence, and communications workflows because risk changes if users move from scribing into clinical-reference or patient-facing tasks. |
Review regional privacy terms, retention, consent, and any de-identified data-improvement rights before using the broader platform with PHI. |
Test the exact Heidi product in scope and measure note quality, evidence reliability, or communications safety separately rather than treating the suite as one workflow. |
Best for teams that want configurable clinician tooling but can govern product-by-product rollout across scribe, evidence, and communication features. |
| ModMed Scribe |
Treat it as specialty documentation and coding-support software unless downstream automation crosses into unsupervised clinical or billing action. |
Review how native EHR integration changes PHI scope, recording-consent workflow, retention, and access controls for your specialty deployment. |
Validate specialty note quality and coding suggestions in the real EMA workflow before trusting downstream automation or specialty-specific claims. |
Best for specialty groups where built-in EMA integration matters more than a standalone ambient scribe with broader EHR reach. |
| Augmedix |
Treat Augmedix as documentation workflow support unless a local implementation adds coding, ordering, or clinical decision functionality that changes intended use. |
Hybrid human-assisted models require extra review of workforce access, offshore or subcontractor handling, recording consent, retention, and BAA terms beyond generic AI-scribe checks. |
Pilot each mode separately because AI-only and human-assisted documentation can differ in turnaround time, note quality, clinician edits, and operational cost. |
Best evaluated where teams need a governed documentation operating model rather than only a self-serve scribe app. |
| Commure Ambient AI |
Treat documentation as lower-to-medium risk, but separately review AI Assistant, CareCues, autonomous coding, and revenue-cycle features because each can change clinical, coding, or compliance accountability. |
Confirm BAA path, HIPAA scope, audio and transcript retention, training-data use, clinician preference learning, EHR access, audit logs, and subcontractor controls before using PHI. |
Validate note quality, specialty fit, coding cue accuracy, prior-history summarization, and generated care-plan content against real encounters before expanding. |
Best governed as EHR-connected clinician support with explicit consent, clinician editing, final signoff, exception queues, and separate approval for coding or billing automation. |
| Tali AI |
Treat Tali as draft documentation and dictation support unless a deployment adds clinical advice, coding automation, or patient-facing use that changes review obligations. |
Review the exact regional product terms for audio deletion, transcript retention, data residency, BAA or data-processing agreement coverage, subprocessors, and model-training restrictions. |
Validate note accuracy, specialty terminology, hallucinated facts, missing negatives, and template fit on local encounters before using generated notes at scale. |
Best governed as a clinician-controlled scribe with recording consent, draft status, final signoff, EHR insertion checks, and documented correction tracking. |
| Twofold Health |
Treat as clinician-reviewed note drafting, not autonomous diagnosis, therapy assessment, coding, or treatment planning without a professional review boundary. |
Behavioral health and therapy use needs extra review of consent language, psychotherapy-note segregation, minimum necessary access, BAA terms, retention, and deletion workflow. |
Test session-note quality across visit lengths, modalities, speakers, and required formats, with specific review for invented findings or inappropriate therapy-plan language. |
Best governed as a draft-note assistant where the clinician controls recording, edits every note, manages EHR transfer, and documents patient consent. |
| Nabla Copilot |
Treat as clinician-reviewed documentation and workflow support unless coding, patient-instruction, or real-time intelligence features are configured in ways that affect clinical or billing decisions. |
Review BAA terms, audio capture, transcript and note retention, optional feedback audio, de-identification, EHR context, API logs, subprocessors, model-training restrictions, and organization-specific retention controls. |
Validate note accuracy, specialty language, coding-support precision, patient-instruction safety, edit burden, and clinician satisfaction against local encounters before broad rollout. |
Best governed with consent scripts, draft-note labeling, clinician signoff, EHR insertion review, template ownership, exception reporting, and separate approval for coding or patient-facing outputs. |
| Eleos Health |
Treat as behavioral health documentation, compliance, and care operations support; confirm whether any workflow-agent or predictive decision-support capability creates additional health IT or state-law obligations. |
Review client consent, psychotherapy-note boundaries, audio and transcript deletion, AI suggestions retained for model refinement, EHR embedding, geographic data residency, access controls, BAA terms, and minimum-necessary staff access. |
Validate note quality, compliance flags, word-error performance, provider workload, Medicaid audit defensibility, and equity across programs, accents, languages, and visit types. |
Best deployed with clinical documentation integrity ownership, compliance-review queues, provider training, client notice language, EHR transfer rules, and routine audit of AI-suggested content. |
| TORTUS |
Treat TORTUS as documentation support under UK clinical-safety and information-governance review; verify current DTAC, DCB0129/DCB0160, procurement, and local approval status before rollout. |
Review UK GDPR lawful basis, processor/controller roles, retention, deletion, subprocessor, security, browser capture, cloud processing, and patient notice requirements. |
Validate note and code output against local NHS documentation standards, specialty workflows, clinician edits, safety incidents, and patient opt-out handling. |
Best governed as a clinician-reviewed NHS scribe workflow with local DPIA, patient notice, opt-out path, final signoff, and post-deployment safety monitoring. |
| NextGen Clinical AI |
Treat as clinician-reviewed documentation and EHR workflow support; verify whether any coding, medication, lab, imaging, or order suggestion is governed locally as clinical decision support or revenue-cycle support. |
Review recording notice and consent, transcript retention, audio deletion, mobile capture, EHR insertion, BAA terms, access logs, hosted-data controls, ISO scope, and whether generated content can be used for product improvement. |
Validate specialty note quality, clinician edits, hallucinated or omitted details, coding suggestion accuracy, patient-summary usefulness, and workflow impact against representative encounters before broad rollout. |
Best governed as a NextGen-native ambient documentation workflow with explicit provider review, patient notice, mobile-device policy, EHR signoff, and monitoring of note defects and suggestion overrides. |
| Aidoc |
Verify the exact Aidoc algorithm, version, modality, anatomy, intended use, quality-system documentation, and FDA or local authorization before clinical deployment. |
Review DICOM routing, AWS or Azure processing, metadata handling, retention, access controls, trust-center evidence, and security documentation for the selected PACS/RIS workflow. |
Evaluate performance by finding and site, including false positives, false negatives, alert fatigue, turnaround-time impact, and downstream care-team response. |
Best governed as radiology triage and care-coordination support, with radiologist review, escalation rules, and post-deployment monitoring for every enabled module. |
| Viz.ai |
Do not treat a platform-level FDA-cleared-algorithm count as clearance for every pathway; verify the specific disease module, indication, and geography. |
Check imaging, mobile, messaging, and EHR data flows, including notification content, user access, trust-center controls, retention, and business-associate terms. |
Review pathway-specific evidence for time-to-notification, treatment activation, false alerts, missed cases, and outcome measures in comparable hospitals. |
Use when the care pathway has named responders, escalation windows, and specialist confirmation rather than as standalone diagnostic interpretation. |
| Ferrum Health |
Treat Ferrum as governance and deployment infrastructure; regulatory review still needs model-by-model intended-use, clearance, local-validation, and change-management checks. |
Review whether deployment is on-premises, private cloud, or vendor-connected, then verify PHI routing, de-identification, retention, deletion, encryption, access control, BAA, and subprocessor terms. |
Require local validation and ongoing monitoring for every model in the catalog, including scanner mix, patient population, drift, false positives, false negatives, and downstream action rates. |
Best used when a health system has a clinical AI governance committee, named model owners, incident review, and post-deployment monitoring rather than isolated AI pilots. |
| Blackford Platform |
Treat Blackford as deployment infrastructure plus a marketplace; verify regulatory status, intended use, and local authorization for each algorithm routed through it. |
Review the on-prem connector, cloud application paths, DICOM metadata, PACS/RIS/EMR links, retention, HITRUST documentation, subprocessors, and customer contract terms. |
Evaluate algorithm-level evidence and platform operational metrics separately, including routing accuracy, uptime, failure handling, monitoring, and radiologist interaction. |
Best governed as enterprise imaging AI infrastructure with radiology, IT, security, clinical engineering, and governance review before adding each algorithm. |
| CARPL.ai |
Treat CARPL as a cleared imaging platform plus marketplace; verify K232891 scope, software version, intended users, modalities, geography, and the separate regulatory status of every connected AI algorithm before clinical use. |
Map DICOM image flow, metadata, account data, viewer access, cloud or local deployment, retention, support access, storage regions, subprocessors, research or analytics rights, and BAA or data-processing terms. |
Evaluate platform reliability, routing, viewer behavior, validation tooling, monitoring coverage, and each algorithm's local performance separately across scanner mix, patient population, prevalence, and radiologist interaction. |
Best governed as enterprise radiology AI infrastructure with radiology, IT, security, legal, procurement, and clinical AI governance approval before enabling each marketplace application. |
| deepcOS |
Treat deepcOS as an AI deployment platform plus marketplace; verify regional clearance, intended use, version, and clinical responsibility for every algorithm or reporting module enabled through it. |
Review cloud or on-premise deployment, DICOM data flows, metadata, role access, encryption, pseudonymization, retention, data-processing terms, subprocessors, and security attestations before sending imaging studies. |
Evaluate algorithm-level evidence separately from platform evidence, then test routing accuracy, monitoring coverage, local-data evaluation, alert handling, and radiologist interaction in a pilot. |
Best governed as enterprise radiology AI infrastructure owned jointly by radiology, imaging IT, security, procurement, clinical engineering, and AI governance before adding each marketplace application. |
| Enlitic ENDEX |
Treat ENDEX primarily as imaging data-management infrastructure, then review any claims or connected workflows that affect clinical interpretation, routing priority, billing, de-identification, or downstream AI-model deployment. |
Map DICOM metadata, pixel data, burned-in PHI, identifiers, re-identification keys, audit logs, archive exports, customer portal access, subprocessors, and retention before using it for migration or research workflows. |
Validate data-normalization accuracy against representative local studies, modalities, historical descriptions, edge cases, hanging protocols, routing rules, billing fields, and downstream analytics queries. |
Best governed as radiology data-quality infrastructure owned jointly by imaging IT, PACS administration, radiologists, compliance, and data-governance teams before enabling broad archive or AI-readiness workflows. |
| Brainomix 360 Stroke |
Review each Brainomix module separately because e-ASPECTS, e-CTA, Triage Stroke, core-volume, e-MRI, mobile alerts, and regional releases can carry different indications and clearance status. |
Map DICOM transfer, on-premises or cloud processing, pseudonymized mobile notifications, user access, retention period, secure deletion, and customer contract terms before production routing. |
Evaluate acute-stroke evidence against the local pathway, including scanner mix, ASPECTS agreement, LVO detection, core-volume estimation, false-positive burden, thrombectomy activation, and transfer outcomes. |
Best governed as specialist-reviewed stroke decision support with named responders, escalation windows, downtime handling, audit trails, and post-deployment monitoring for alert quality and treatment delays. |
| Avicenna.AI CINA-ASPECTS |
Match CINA-ASPECTS to FDA 510(k) K233342, local CE or other market status, exact intended use, software version, age range, scanner manufacturer, and acute-stroke context before using outputs in care decisions. |
Review DICOM routing, identifiers, cloud or on-premise processing, user access, audit logs, retention, support access, incident response, and customer data-processing terms; the public privacy policy mainly covers website interactions and points buyers to compliance documents. |
Evaluate performance on local non-contrast head CT studies against neuroradiologist or stroke-team ASPECTS assessment, including artifacts, scanner mix, early ischemic changes, excluded pathologies, and treatment-decision impact. |
Best governed as clinician-reviewed ASPECTS decision support inside an acute stroke protocol, with explicit ownership for reviewing heat maps, resolving AI-clinician disagreement, documenting decisions, and monitoring drift. |
| Qure.ai |
Separate each Qure.ai product and regional deployment because chest X-ray, CT, TB, lung-nodule, and stroke workflows may have different authorization status. |
Review image routing, cloud or local deployment, de-identification before cloud processing, retention, public-health data sharing, DICOM metadata handling, and cross-border processing terms. |
Validate performance for the target population, prevalence, scanner mix, and clinical pathway, especially when moving from public-health screening into hospital care. |
Best evaluated with radiologist or clinician review, escalation rules, and equity monitoring for false positives and false negatives across deployment sites. |
| Qure.ai qXR |
Treat qXR as a family of chest X-ray AI functions rather than one universal clearance; match qXR-LN, qXR-BT, qXR-PTX-PE, qXR-CTR, or any newer module to the exact indication, version, anatomy, geography, and user workflow. |
Review whether images are de-identified before cloud processing, whether deployment is cloud or on-premise, how DICOM metadata, overlays, reports, audit logs, retention, and cross-border transfers are handled, and whether contract terms cover PHI. |
Require local validation by finding and workflow, including scanner types, adult population, prevalence, reporting queue effects, false-positive burden, missed critical findings, and equity across deployment sites. |
Best governed as radiologist-reviewed chest X-ray assistance with documented worklist rules, report-review boundaries, escalation paths, downtime procedures, and post-deployment monitoring. |
| Oxipit ChestLink |
Treat ChestLink as a high-risk autonomous radiology workflow and verify the exact CE Class IIb certificate, intended use, country availability, version, and absence or presence of FDA authorization before any clinical deployment. |
Review DICOM image routing, patient identifiers, RIS/PACS integration, analytics dashboards, support access, retention, security controls, and the customer data-processing agreement rather than relying on the public website privacy notice. |
Require local retrospective validation and supervised operation data before autonomous release, with special attention to false negatives, abnormality prevalence, scanner mix, excluded cases, and monitoring sensitivity. |
Best governed as a staged autonomous-normal-CXR program with explicit release thresholds, radiologist oversight for all uncertain or abnormal cases, audit review, downtime fallback, and safety-event escalation. |
| Rad AI |
Treat reporting assistance separately from image-interpretation software; verify whether guideline insertion, discrepancy detection, or local configuration changes clinical decision-support or quality-system obligations. |
Review how dictated findings, report drafts, identifiers, templates, worklists, EHR/RIS data, audit logs, de-identification, retention, and model-improvement terms are handled. |
Pilot against local report templates, modalities, and subspecialties, tracking clinically significant omissions, incorrect impressions, turnaround time, edit burden, discrepancy catches, and radiologist satisfaction. |
Best used as radiologist-controlled report drafting where the interpreting physician remains responsible for final report content, consensus-guideline wording, discrepancy resolution, and QA. |
| Rad AI Continuity |
Treat as radiology workflow and patient-safety infrastructure; reassess risk if the system changes recommended follow-up timing, patient instructions, escalation criteria, or care-team prioritization beyond the radiologist's report. |
Review report ingestion, patient identifiers, messaging channels, EHR/RIS links, provider fax or EHR messages, direct mail, audit logs, retention, access controls, and BAA or security documentation. |
Validate against local reports and follow-up programs by measuring extraction accuracy, missed recommendations, inappropriate outreach, completion rates, navigator workload, subgroup performance, and downstream outcomes. |
Best governed as a closed-loop radiology follow-up program with radiology, ordering-provider, navigator, compliance, and patient-communication ownership explicitly assigned. |
| Cleerly |
Confirm product-specific clearance, Rx-only status, trained-user requirements, indication, eligible CCTA acquisition protocol, and geography before using plaque analysis in a clinical pathway. |
Review coronary CTA upload, cloud processing, image retention, report distribution, authorized users, application access, and data-use terms for cardiology workflows. |
Evaluate evidence for the intended patient population, scanner protocols, plaque metrics, downstream testing, preventive treatment decisions, and follow-up outcomes. |
Best governed as cardiologist-reviewed CCTA analysis feeding structured prevention or treatment-planning workflows, not as autonomous cardiovascular diagnosis. |
| Elucid PlaqueIQ |
Match the PlaqueIQ version, 510(k) record, indication, CCTA acquisition requirements, geography, and reimbursement use before adding it to a clinical pathway. |
Review coronary CTA upload, remote access to PHI, encrypted transfer, retention, support access, subcontractors, customer-controller obligations, and DPF or local transfer terms. |
Assess validation for the target CCTA population, scanner/protocol mix, plaque-composition metrics, lesion-level outputs, reader agreement, and downstream treatment or testing decisions. |
Best governed as physician-reviewed coronary CTA plaque analysis feeding structured cardiology risk assessment, prevention, referral, and follow-up workflows. |
| LumineticsCore |
Because this is positioned as autonomous diagnostic AI, match use exactly to the FDA-cleared indications, contraindications, trained operators, Topcon camera requirement, and required workflow. |
Review retinal-image capture, device connectivity, diagnostic-result hosting, storage, access controls, report delivery, referral communication, and patient-consent documentation. |
Monitor unreadable-image rates, false positives, false negatives, referral completion, and local prevalence instead of relying only on clearance status. |
Best suited to protocolized diabetic-eye-exam workflows with defined eligibility screening, patient instructions, referral routing, billing, and quality oversight. |
| Eyenuk EyeArt |
Match deployment to the current FDA-cleared EyeArt version, indication, supported cameras, trained-user requirements, adult diabetes population, geography, and referral workflow. |
Review retinal-image upload, cloud processing, API integrations, EHR/PACS connectivity, encryption, retention, support access, audit logging, BAA terms, and privacy/security contacts before sending PHI. |
Validate performance locally across camera model, operator skill, image quality, disease prevalence, patient demographics, false-positive burden, missed-referral risk, and follow-up completion. |
Best governed as an autonomous screening workflow with eligibility checks, trained image capture, report review, referral routing, documentation, billing, and post-deployment quality monitoring. |
| AEYE-DS |
Match deployment to the current AEYE-DS 510(k), camera, indication, contraindications, trained-user workflow, eligible adult diabetes population, and local diagnostic-screening rules. |
Review retinal-image capture, identifiers, EHR ordering and result return, de-identified model-improvement use, U.S. hosting, retention by provider agreement, access controls, and BAA or data-processing terms. |
Validate local performance against the clinic's camera, operator skill, image-quality rate, patient demographics, disease prevalence, follow-up capacity, and expectations for non-diabetic eye disease. |
Best governed as a protocolized care-gap closure workflow with eligibility checks, trained capture, report review, referral routing, billing review, and quality monitoring. |
| RETINA-AI Galaxy |
Use only within the current FDA-cleared indication, camera list, adult diabetes population, contraindications, warnings, and physician-review workflow. |
Request current HIPAA audit evidence, BAA terms, image and report retention, support access controls, EHR export details, and any secondary-use or model-improvement terms. |
Review pivotal-study results and run local monitoring by camera, operator, image quality, dilation rate, disease prevalence, false-negative risk, and referral follow-through. |
Best governed as autonomous screening that still requires physician review of results, patient instructions, retest or referral rules, and follow-up tracking. |
| RetInSight Fluid Monitor |
Verify current MDR/CE status, local availability, intended nAMD use, OCT compatibility, and whether any U.S. use is investigational, research-only, or otherwise restricted. |
Review OCT upload, cloud or local processing, patient identifiers in reports, retention, user access, export controls, support access, and clinic data-processing terms. |
Validate segmentation and volumetric trends against specialist review for local OCT devices, scan quality, disease severity, treatment intervals, and fluid types. |
Best governed as retina-specialist-reviewed OCT quantification and monitoring support, with documented override rules and treatment decisions made outside the algorithm. |
| RetinAI Discovery |
Confirm device status by region and module, because the Discovery platform, CE-marked AI modules, FDA-cleared platform claims, and U.S. RUO AI-module limits may differ. |
Review DICOM/proprietary image storage, data-sharing permissions, real-world evidence reuse, role access, cloud hosting, GDPR/HIPAA/PIPEDA posture, DPA terms, and study contracts. |
Assess validation for the exact retinal disease, OCT/device source, AI module, endpoint, and clinic or research workflow before relying on extracted measurements. |
Best governed as a secure retinal imaging data and AI-enrichment layer with ophthalmologist, reader, or study-team review before clinical or trial decisions. |
| RapidAI |
Validate the selected RapidAI module against its own clearance, modality, anatomy, and intended use rather than applying platform claims across all workflows. |
Review edge, hybrid, on-prem, and cloud deployment choices; PACS/RIS/EHR integration; image routing; mobile notifications; DPF/privacy terms; data retention; uptime; audit logs; and cybersecurity requirements for acute-care use. |
Measure pathway-specific impact on notification timing, transfer decisions, false alerts, missed findings, and downstream outcomes during a controlled rollout. |
Best deployed where stroke, vascular, hemorrhage, or aortic teams have clear alert ownership, escalation rules, downtime procedures, and monitoring dashboards. |
| Heartflow |
Separate FFRCT, plaque, roadmap, and other Heartflow modules because each may have different clearance, indication, contraindication, and reimbursement requirements. |
Review CCTA image submission, cloud analysis, report delivery, retention, access controls, and cardiology-record integration before production use. |
Assess clinical utility for the target coronary-artery-disease population, scanner protocols, image quality thresholds, downstream testing, and treatment changes. |
Best governed as cardiology-reviewed coronary CTA analysis feeding shared decision-making, referral, preventive-care, or cath-lab planning workflows. |
| Ultromics EchoGo |
Match the EchoGo Heart Failure version, 510(k) record, indication, product code, geography, and reimbursement workflow before using output in a heart-failure pathway. |
Review echocardiography upload flow, cloud or integration partner processing, customer-controller obligations, retention, deletion, access controls, DPO contact path, and support-data handling. |
Evaluate HFpEF detection evidence, eligible echo views, image-quality failures, false-positive and false-negative burden, patient population fit, and downstream testing or referral impact. |
Best governed as cardiologist-reviewed echo decision support that feeds HFpEF diagnostic workups, structured reporting, and follow-up planning rather than autonomous diagnosis. |
| Us2.ai |
Match the exact Us2.ai version, intended use, automated parameter set, disease-detection output, geography, and market authorization before using results in clinical echo reporting. |
Review DICOM routing, cloud versus on-premises deployment, regional data residency, PACS/CVIS/report delivery, subprocessors, BAA or data-processing terms, access controls, and support-data handling. |
Validate automated measurements and disease-detection outputs against local echo-lab readers, scanner mix, patient population, image quality, false-alert burden, and downstream clinical decisions. |
Best governed as cardiologist-reviewed echo automation that feeds structured reporting and quality-control workflows, with explicit rules for failed studies, overrides, and post-deployment monitoring. |
| Gleamer BoneView |
Verify BoneView US K222176 and any local CE, Health Canada, or other authorization for the exact module, anatomy, patient age, and clinical site. |
Review imaging-data flow, DICOM metadata, pseudonymized patient data, processor/controller roles, subcontractors, security controls, and retention in the deployment contract. |
Validate performance on local trauma X-rays, pediatric and adult case mix, fracture type, body region, scanner workflow, false positives, false negatives, and report turnaround. |
Best used as a second-reader and prioritization aid inside existing radiology or emergency workflows, with explicit responsibility for accepting, rejecting, and documenting AI marks. |
| iCAD ProFound AI |
Verify the exact ProFound module and version because FDA-cleared detection, density, and risk-related features do not share one blanket authorization. |
Review mammography image routing, DICOM metadata handling, PACS/viewer integration, cloud or local deployment, retention, access controls, and security documentation. |
Check reader-study evidence, breast-density subgroup performance, recall impact, cancer subtype detection, specificity, and whether priors are used in the selected version. |
Map where marks, case scores, density output, risk signals, and worklist prioritization appear in the radiologist workflow before clinical use. |
| GI Genius |
Verify the exact GI Genius module, labeling, De Novo record, software version, intended use, prescription restriction, and country-specific status before using it in screening or surveillance workflows. |
Map whether the deployment processes, stores, transmits, or logs endoscopy video, patient identifiers, room metadata, support diagnostics, and service records under the provider's privacy and security agreements. |
Review clinical evidence for the target screening population, adenoma detection rate, missed lesions, false-positive markers, operator reliance, withdrawal time, and impact on pathology-confirmed outcomes. |
Best governed as real-time endoscopist decision support with explicit rules for training, visual-marker response, biopsy decisions, downtime, documentation, and periodic performance review. |
| SKOUT |
Confirm the SKOUT 510(k), software version, labeling, intended adult population, white-light limitation, component compatibility, and any region-specific availability before clinical use. |
Review endoscopy-video flow, identifiers, support logs, retained quality metrics, processor roles, access controls, deletion, audit logging, and business-associate terms before room integration. |
Evaluate evidence for adenoma and polyp detection, sessile lesions, procedure time, false markers, missed lesions, resection mix, and whether results generalize to local endoscopists and case mix. |
Best governed as an assistive detection overlay with training, over-reliance safeguards, documentation expectations, downtime plans, and ongoing monitoring of colonoscopy quality metrics. |
| Fujifilm CAD EYE |
Match CAD EYE, EW10-EC02, SCALE EYE, and any characterization feature to the exact FDA record, indication, hardware configuration, and market availability because they should not be treated as one blanket authorization. |
Review whether endoscopy images, video, metadata, support diagnostics, service access, and software-update logs stay on local equipment or move through vendor-managed systems. |
Validate clinical evidence for the local colonoscopy population, endoscope hardware, lesion size and morphology, false markers, missed lesions, and effect on procedure quality metrics. |
Best governed as physician-reviewed detection support inside a compatible Fujifilm room, with explicit training, equipment checks, documentation rules, and post-live quality monitoring. |
| Olympus CADDIE |
Match the deployed CADDIE version to the exact FDA 510(k), intended use, white-light limitation, hardware dependencies, and U.S. detection-only scope rather than assuming all OLYSENSE features share one authorization. |
Because the workflow is cloud-connected, map endoscopy video, metadata, network transport, hub logs, support access, retention, security controls, and business-associate terms before installation. |
Review the EAGLE trial, FDA summary data, and local validation for adenoma detection, high-risk lesions, false positives, latency, procedure time, and performance across endoscopists and patient mix. |
Best governed as physician-reviewed real-time detection support with room-readiness checks, connectivity downtime rules, training, documentation expectations, and ongoing quality metric review. |
| MammoScreen |
Match each MammoScreen module and version to its specific FDA, CE, or local authorization because detection, breast density, and workflow assistance should not be treated as one blanket clearance. |
Review mammography image routing, DICOM metadata, SaaS processing, retention, access controls, audit logs, subprocessor terms, and business-associate or data-processing agreements. |
Validate reader-study evidence and local performance for the target modality, density mix, scanner fleet, cancer prevalence, recall patterns, and radiologist interaction model. |
Best governed as radiologist-reviewed breast-screening support with explicit rules for how scores, priors, density output, and draft-report signals influence final interpretation. |
| Kheiron Mia |
Review each module separately because Mia Triage, Mia Reader, Mia IQ, and RSViP may have different intended uses and country-specific authorization paths. |
Assess mammography image flow, patient identifiers, PACS/RIS integration, cloud or distributor processing, retention, access controls, audit logs, and data-processing terms. |
Require local screening-program evidence for detection, recall, workload, image quality, population fit, scanner mix, and post-market monitoring rather than relying only on headline performance claims. |
Best governed as pathway support for radiologist-reviewed screening, with explicit rules for triage thresholds, quality-audit actions, second-reader escalation, and patient-safety review. |
| ScreenPoint Transpara |
Verify the exact Transpara module, version, country, modality, and 510(k) or CE status because detection, density, and comparison features should not be treated as one blanket authorization. |
Review mammography image routing, DICOM metadata handling, cloud or on-prem deployment, retention, access controls, subprocessors, and business-associate or data-processing terms. |
Check evidence for the target screening population, dense-breast subgroup, 2D versus DBT workflow, cancer subtype, recall impact, and radiologist interaction model. |
Best governed as radiologist-reviewed mammography support with local rules for when AI marks or scores change read order, second-read strategy, recall decisions, and documentation. |
| Koios DS Breast |
Match K212616 or the relevant current clearance to the exact breast ultrasound workflow, patient group, lesion type, and trained interpreting-physician use. |
Review ultrasound image transfer, DICOM metadata handling, cloud or local processing, retention, user access, audit logs, and security documentation before sending clinical studies. |
Validate CADx performance on local ultrasound equipment, operator mix, lesion prevalence, benign/malignant balance, subgroup representation, and downstream biopsy decisions. |
Best used as adjunctive physician-reviewed ultrasound decision support, with explicit documentation of ROI selection, AI output review, BI-RADS reconciliation, and final clinician accountability. |
| Subtle Medical |
Treat each Subtle product as a separate imaging device workflow; match clearance, sequence, modality, and intended-use language before changing clinical protocols. |
Verify image transfer, cloud or on-prem processing, retention, DICOM metadata handling, business associate terms, access controls, and vendor security materials. |
Validate image quality, artifact risk, scan-time or dose claims, and radiologist acceptance on local scanner models, protocols, body regions, and patient populations. |
Coordinate radiology, technologist, physicist, PACS, modality, and protocol governance because image-enhancement tools can affect acquisition and interpretation steps. |
| Lunit |
Verify the exact Lunit product, version, modality, anatomy, and intended use against FDA, CE/MDR, and local product-registration materials before clinical deployment. |
Review image routing, cloud or partner integrations, retention, access controls, DICOM metadata handling, security documentation, and any research or training-data terms. |
Require module-level validation for the local population and scanner workflow rather than relying on platform-level publication or site-count claims. |
Map radiologist, breast-imaging, pathology, oncology, PACS/RIS, and escalation workflows separately because Lunit's product family spans multiple clinical pathways. |
| annalise.ai |
Separate U.S. triage-cleared findings from broader regional Enterprise feature sets; not all findings, reporting features, or regions have the same status. |
Review DICOM flow, viewer access, cloud or local deployment, audit logs, retention, and customer security documentation before routing imaging studies. |
Evaluate performance by finding, modality, geography, patient population, radiologist workflow, and reporting-time objective instead of treating 100-plus finding coverage as uniform evidence. |
Define whether AI output changes reporting order, draft reports, critical-findings escalation, or second-reader behavior, then monitor alert fatigue and missed findings. |
| CureMetrix |
Verify cmTriage's FDA-cleared notification-only intended use and do not generalize it to diagnosis, DBT, cmAssist, or any region-specific product without separate clearance review. |
Review DICOM routing, cloud processing, hospital-network integration, metadata handling, retention, access controls, and contract terms before routing mammography studies. |
Evaluate local breast-density mix, scanner workflow, suspicious-case prioritization, recall impact, and radiologist performance rather than relying only on vendor benchmark claims. |
Best treated as breast-imaging worklist prioritization that supports standard radiologist interpretation, with monitoring for alert fatigue and missed suspicious cases. |
| Hologic Genius AI Detection |
Match the installed version to the correct FDA 510(k), product code, compatible Hologic systems, and intended use before applying case scores or markers clinically. |
Review whether images, case scores, logs, support data, or remote-service access leave the facility, and confirm retention, access-control, audit, and contract terms. |
Evaluate reader-study evidence and local monitoring for cancer detection, recall, breast-density mix, false markers, missed cancers, and effects on radiologist workload. |
Best governed as radiologist-reviewed breast-screening CAD support where AI marks and case scores inform but do not replace final interpretation. |
| GE HealthCare Caption AI |
Separate scan-guidance features, automated measurement software, and the ultrasound hardware because each can have different cleared indications, compatible systems, and trained-user expectations. |
Review device connectivity, image and measurement storage, PACS/EHR export, user access, service telemetry, cloud features, retention, and customer security documentation for ultrasound deployments. |
Pilot with the target clinician group and patient mix, measuring diagnostic-quality view acquisition, unusable scans, measurement disagreement, credentialing outcomes, and downstream echo utilization. |
Best governed as assisted image acquisition and measurement support with explicit credentialing, QA review, escalation for inadequate studies, and qualified clinician interpretation. |
| Butterfly iQ3 |
Separate the iQ3 ultrasound system, education tools, workflow software, and gestational-age AI because hardware clearance and AI-tool clearance do not authorize every clinical use. |
Review cloud exam storage, device-user identity, mobile-device controls, sharing links, retention, support access, EHR/PACS export, and enterprise data-processing terms. |
Validate image quality, measurement reliability, user training outcomes, gestational-age workflow performance, and follow-up completion for the intended care setting. |
Best deployed with POCUS governance: operator credentialing, QA overreads, exam protocols, escalation rules, connectivity fallback, and documentation ownership. |
| Sonio Detect |
Match the deployed Sonio Detect version to the exact FDA 510(k), intended use, compatible ultrasound systems, supported gestational ages, and local regulatory clearance before clinical use. |
Review cloud upload, DICOM and clip handling, HL7/EHR integration, user identity, support access, retention, subprocessors, and BAA or regional data-processing terms. |
Pilot against local prenatal ultrasound protocols and track view acquisition, quality-check agreement, false confidence, repeat scans, referral patterns, and subgroup performance. |
Best governed as acquisition and quality-control support for trained ultrasound users, with specialist interpretation, documentation, escalation, and patient communication remaining outside the AI. |
| DeepHealth Breast Suite |
Separate each Breast Suite component before deployment because FDA clearance for Saige-Dx does not automatically cover risk assessment, breast ultrasound, BAC, viewer, or future suite modules. |
Review mammography image routing, cloud processing, PACS or worklist integration, user roles, support access, retention, audit logging, BAA terms, and regional data-processing commitments. |
Pilot against local mammography baselines for cancer detection, recall, reading time, density distribution, subgroup performance, scanner mix, and radiologist disagreement rather than relying on broad suite claims. |
Best governed as radiologist-reviewed breast imaging decision support with module-specific protocols, quality monitoring, override capture, escalation rules, and clear patient communication boundaries. |
| Pearl Second Opinion |
Match the exact Pearl module, 2D or 3D modality, patient age, anatomy, and intended use to FDA and local clearance before using findings in diagnosis or treatment planning. |
Review Pearl's data-protection, privacy, BAA, image-retention, support-access, and cross-border processing terms before routing identifiable dental images. |
Validate local performance on bitewing, periapical, panoramic, and CBCT workflows separately, including false positives, missed findings, dentist overrides, and patient-education effects. |
Best governed as a dentist-reviewed second-reader and patient-communication layer, with clear rules for editing findings and documenting final clinical judgment. |
| Overjet |
Review each FDA clearance separately because caries detection, bone-level measurement, pediatric claims, image enhancement, CBCT, payer review, and voice workflows have different intended uses. |
Confirm BAA terms, HIPAA policy, encryption, image and PMS-data retention, patient scheduling data handling, vendor access, and payer-provider data boundaries. |
Pilot against local dental images and charting standards, tracking missed lesions, extra findings, periodontal measurements, image-enhancement artifacts, and dentist overrides. |
Best deployed with dentist review, patient-communication scripts, PMS/imaging integration testing, payer-use separation, and monitoring for over-treatment or inconsistent documentation. |
| VideaAI |
Separate FDA-cleared Clinical Assist detections from patient education, voice, claims, dashboard, and operational analytics features that may not share the same intended use. |
Review customer agreements, privacy terms, data retention, image/PMS integration, user access, support access, and analytics use before deploying across practices. |
Validate per finding and age group on local dental radiographs, including pediatric cases, calculus, PARL, caries, bone level, false positives, and dentist overrides. |
Best governed as clinician-reviewed radiograph support with explicit patient-education boundaries, rollout training, and monitoring for treatment-plan and documentation effects. |
| Denti.AI |
Separate Detect, Auto-Chart, Voice Perio, Scribe, receptionist, and voice-assistant features because imaging-device clearance does not automatically cover every documentation or communications workflow. |
Review image, voice, PMS, SMS, analytics, retention, transfer, support-access, BAA, and customer-contract terms before routing identifiable dental data through connected services. |
Pilot on local radiographs and charting workflows, tracking per-finding sensitivity, false positives, missed findings, perio-chart corrections, note defects, and dentist overrides. |
Best governed as dentist-reviewed imaging and documentation support, with explicit patient-consent language for voice features, PMS write-back controls, and quality sampling before scaling. |
| Diagnocat |
Use the FDA-cleared CBCT indication narrowly: second-read support for periapical radiolucency in permanent teeth for trained dental professionals, not a replacement for complete clinical judgment. |
Review DICOM routing, cloud storage, desktop or web viewer access, report sharing, support access, HIPAA materials, SOC 2 evidence, retention, and business-associate terms. |
Validate against local CBCT cases, scanner protocols, oral-radiologist review, periapical-radiolucency prevalence, segmentation accuracy, and how often clinicians dismiss AI findings. |
Best deployed after CBCT necessity is independently determined, with clinician review of heat maps, report edits, patient-communication boundaries, and documented final interpretation. |
| DentalMonitoring |
Match use to DEN230035 and local MDR/CE scope, including patient age, permanent teeth, cleared indications, orthodontist oversight, and country-specific product availability. |
Review patient app data, photos, scan metadata, messaging, clinician accounts, cloud processing, retention, transfers, consent, support access, and data-processing terms. |
Assess local scan quality, false alerts, missed treatment-tracking issues, visit reduction claims, patient adherence, subgroup performance, and clinician response times. |
Best governed as clinician-supervised remote orthodontic monitoring, with protocols for no-go alerts, patient messages, scan failures, in-office escalation, and record documentation. |
| DermaSensor |
Treat as regulated prescription medical-device software and hardware; match use to DEN230008, age limits, lesion exclusions, trained users, adjunctive role, and post-market performance expectations. |
Review device connectivity, cloud synchronization, software updates, remote monitoring, identifiers, access controls, BAA terms, retention, and support workflows before clinical rollout. |
Assess FDA summary evidence and local pilot data for sensitivity, specificity, false reassurance, false referral, skin type, lesion location, and prevalence differences. |
Best governed as a suspicious-lesion referral aid where clinicians first identify eligible lesions, interpret the AI output with clinical findings, document decisions, and track biopsy or dermatology follow-up. |
| Skin Analytics DERM |
Verify the exact jurisdiction and pathway because CE-marked UK deployment, MHRA oversight, NHS use, and U.S. investigational status create different obligations. |
Review dermatology-image capture, teledermatology routing, identifiers, data protection, ISO 27001, GDPR, NHS DSP Toolkit, DTAC, retention, support access, and patient notice. |
Use post-market surveillance and independent evaluations as starting evidence, then validate local imaging quality, lesion mix, melanoma prevalence, equity, and escalation outcomes. |
Best governed as a pathway-level triage system with explicit image acquisition standards, dermatologist review rules, safety-netting, audit, incident review, and patient communication. |
| FotoFinder Moleanalyzer pro |
Confirm device/software version, country, intended use, compatible FotoFinder hardware, and labeling before using AI score or heatmap outputs in clinical care. |
Review FotoFinder Hub account use, anonymized image transfer for online AI scoring, local offline options, ports, server access, image storage, consent, and data-protection terms. |
Validate on local dermoscopy images with supported magnification, artifacts, calibration quality, lesion types, biopsy outcomes, and clinician disagreement review. |
Best governed as dermatologist-supervised dermoscopy support with manual assessment, longitudinal comparison, second opinion when needed, and final diagnosis outside the AI score. |
| DermEngine |
Separate image management, teledermatology workflow, analytics, mole matching, and any diagnostic support claim because each can carry different local obligations. |
Review cloud storage, mobile apps, MoleScope images, patient portal, consent forms, referral networks, retention, encryption, access controls, and enterprise privacy terms. |
Validate matching, tracking, search, and workflow outputs against local image quality, lesion history, skin tone, and specialist review rather than treating platform analytics as diagnosis. |
Best governed as dermatology image infrastructure with explicit rules for who reviews images, how changes are escalated, and how outputs enter the clinical record. |
| SkinVision |
Confirm country availability, EU MDR certification, medical-device status, patient-facing claims, and whether local deployment creates additional clinical or payer obligations. |
Review photo upload, encryption, deletion, dermatologist review, account data, insurer or partner data sharing, consent, retention, and cross-border processing before recommending use. |
Review published validation and monitor false reassurance, missed malignancy, skin-tone performance, image quality, user adherence, and escalation completion. |
Best governed as access and awareness support with clear safety-net language, clinician referral paths, no diagnostic substitution, and review of high-risk or uncertain results. |
| Paige |
Verify the exact Paige product, scanner, tissue type, and intended use, especially for prostate workflows that have FDA-authorized claims. |
Review whole-slide image storage, cloud processing, LIS links, access controls, retention, and any secondary-use terms before diagnostic deployment. |
Validate performance in the local lab across scanner, stain, tissue preparation, case mix, pathologist workflow, and cancer-prevalence differences. |
Best used as pathologist-supervised digital pathology support where suspicious regions, exceptions, and final diagnostic responsibility remain reviewable. |
| PathAI |
Distinguish AISight image-management, AISight Dx, partner algorithms, and research-only AI tools before treating any workflow as diagnostic. |
Review slide storage, cloud hosting, LIS integration, user roles, audit logs, retention, and customer data-use terms for lab operations. |
Validate scanner compatibility, image quality, algorithm performance, pathologist review burden, and lab population fit before routine diagnostic use. |
Best evaluated as a digital-pathology platform with AI access, requiring lab validation, pathologist signout controls, and clear separation of RUO and diagnostic tools. |
| Hologic Genius Digital Diagnostics |
Confirm the exact cleared system components, ThinPrep cervical cytology intended use, region, and current recall or correction status before clinical use. |
Review image-management storage, remote review, access controls, audit logging, support access, retention, and cytology LIS integration under customer contract terms. |
Validate sensitivity, specificity, abnormal-cell gallery behavior, cytotechnologist workload, pathologist escalation, and quality-control effects in the local screening population. |
Best evaluated as a full cytology workflow change where AI prioritization, review-station ergonomics, QA, and final signout are governed together. |
| Ibex Medical Analytics |
Verify the specific Galen module, tissue type, geography, scanner, and intended use; do not generalize Ibex's U.S. 510(k), CE-IVD, IVDR, or other regional claims across all cancer workflows. |
Use the customer agreement, BAA or regional data-processing terms, DICOM/WSI transfer path, retention, DPF/GDPR controls, access logs, and deployment model rather than the public website privacy policy alone. |
Review validation by organ system, stain, scanner, case mix, false-negative risk, biomarker endpoint, and structured-reporting workflow before routine clinical use. |
Best governed as pathologist-supervised cancer-diagnostics support with explicit signout responsibility, exception review, LIS/reporting integration, and post-deployment QA. |
| Deep Bio DeepDx Prostate |
Confirm the exact DeepDx Prostate module, specimen type, region, CE or MFDS status, and U.S. RUO limitation; do not treat CE or Korea MFDS approval as FDA clearance. |
Review cloud or on-premise architecture, WSI and metadata handling, LIS/viewer integration, access controls, support access, retention, regional hosting, and customer data-processing terms. |
Evaluate validation evidence and local performance for prostate biopsy slides, scanner/stain variability, Gleason-pattern accuracy, false-negative risk, edit burden, and final-report impact. |
Best governed as pathologist-supervised diagnostic support with mandatory overlay review, editable annotations, exception tracking, second-read escalation, and manual signout fallback. |
| Proscia |
Separate Concentriq AP-Dx primary-diagnosis clearance from Concentriq AP, Concentriq LS, third-party AI applications, and research workflows; scanner and specimen limitations matter. |
Confirm hosting, storage, scanner ingestion, LIS integration, user roles, collaboration access, retention, audit logs, and contract terms for diagnostic and life-sciences deployments. |
Review the multi-site primary-diagnosis study and any AI-application evidence against the lab's scanner, tissue, specimen, pathologist, and workload context. |
Best evaluated as a digital-pathology operating layer where primary diagnosis, AI launch, collaboration, and data-science workflows each need separate governance. |
| Aiforia |
Match every Aiforia model to its CE-IVD, RUO, PSO, FDA, or local status; EU/EEA diagnostic claims for selected models should not be applied to all suites or markets. |
Verify cloud processing, hosting region, slide upload, scanner integration, retention, customer data-processing terms, access controls, audit logs, and whether public website privacy terms are separate from clinical deployment terms. |
Assess model-level performance by cancer type, tissue, stain, scanner, biomarker threshold, grade group, case prevalence, and pathologist review burden. |
Best used as pathologist-controlled whole-slide image support where overlays, quantitative scores, triage, case review, and final report responsibility remain explicit. |
| Mindpeak |
Verify the exact module, intended use, CE-IVD or local status, ISO 13485 scope, and whether the planned workflow is diagnostic, research, pharma, or deployment-specific. |
Do not infer PHI terms from the public website privacy policy alone; require customer-contract, hosting, retention, access-control, scanner/LIS integration, and data-use terms. |
Review product-specific validation and publications for the tissue, stain, biomarker, scanner, patient population, and scoring threshold used in the lab. |
Map how AI hotspots, biomarker scores, tumor regions, and exceptions appear in the pathologist viewer and report before diagnostic use. |
| Aignostics |
Treat Atlas H&E-TME as research-use pathology AI unless Aignostics provides product-specific diagnostic authorization for the intended workflow. |
Verify customer-contract data handling, GDPR scope, ISO 27001 controls, processing location, retention, deletion, and slide-identification handling before upload. |
Review the validation benchmark for each cancer type, tissue segment, cell class, scanner/stain context, and quantitative endpoint used in the research protocol. |
Keep outputs in translational research, biomarker discovery, or study-analysis workflows with scientific review rather than clinical reporting. |
| Lumea |
Separate Viewer+ primary-diagnosis claims from BxLink, AI marketplace tools, molecular-ordering workflows, and tissue-handling products; each module and partner algorithm needs its own intended-use review. |
Review HIPAA/HITECH documentation, endpoint controls for remote pathologists, encryption, authentication, image storage, AI partner integrations, LIS data flow, retention, and customer-contract terms. |
Check viewer validation, scanner compatibility, specialty workflow claims, AI partner evidence, molecular-ordering performance, and local turnaround-time or diagnostic-quality metrics. |
Best evaluated as a full pathology operating workflow where specimen handling, slide viewing, AI review, molecular ordering, and final signout are mapped together. |
| Visiopharm |
Treat each APP independently because diagnostic, IVDR-certified, CE-IVD, RUO, EU/UK, U.S., and partner-integration status can differ by use case. |
Verify data-processing agreements, customer-data roles, image storage, cloud or local deployment, research-data sharing, access controls, retention, and partner-platform data paths. |
Review APP-level validation for tissue, stain, biomarker threshold, scanner, laboratory population, performance evaluation, and post-market follow-up before clinical use. |
Best used where AI outputs remain reviewable inside existing pathology platforms and where lab teams can govern APP selection, batch processing, QA, and signout. |
| Tribun Health |
Match CaloPix, TeleSlide, AI Apps, and partner modules to regional FDA, CE, Health Canada, RUO, EULA, and AI Module Terms before diagnostic deployment. |
Review hosting, Azure or local storage, remote access, scanner ingestion, LIS/PACS/EHR integration, customer data-processing terms, role access, audit logs, retention, and AI module data flow. |
Assess validation and operational evidence for viewer performance, scanner compatibility, AI module accuracy, archive retrieval, second-opinion workflows, and user adoption in comparable labs. |
Best evaluated as an image-management and AI-integration platform where pathologist review, second-opinion routing, telepathology, and final signout remain explicit. |
| Roche navify Digital Pathology |
Match Roche Digital Pathology Dx, navify Digital Pathology, scanner/display configuration, specimen type, geography, and each AI algorithm to country-specific labeling, FDA 510(k), RUO, or local diagnostic-use status. |
Review Roche digital trust materials, cloud hosting, Amazon S3 storage, encryption, authentication, audit logs, user roles, LIS/PACS data exchange, support access, BAA or DPA terms, and third-party algorithm data paths. |
Validate scanner compatibility, viewer performance, image quality, algorithm accuracy, pathologist workload, LIS/PACS integration, downtime handling, and local specimen variability before clinical use. |
Best governed as an enterprise digital-pathology operating layer where viewing, case collaboration, AI analysis, analytics, and final pathologist signout each have explicit boundaries. |
| PathPresenter |
Separate the FDA-cleared Clinical Viewer configuration from ConsultConnect, education, biorepository, third-party AI models, other scanners/displays, non-U.S. regions, and research-use workflows. |
Verify contractual HIPAA/BAA or DPA terms, cloud versus hybrid storage, de-identification requirements, user roles, remote consult sharing, audit logs, retention, and AI model data pathways before uploading patient slides. |
Review FDA 510(k) materials, local scanner/display validation, pathologist viewer performance, consult turnaround, AI model validation, and any institution-specific V&V results before clinical signout use. |
Best evaluated as a digital-pathology operating layer where image management, primary viewing, remote consults, education, research, and AI model testing each have explicit governance boundaries. |
| DoMore Diagnostics Histotype Px Colorectal |
Confirm CE-IVD or other local status for the exact version, market, stage II/III colorectal indication, and whether the deployment is diagnostic, research, or platform-enabled. |
Review slide upload, hosting, customer-contract data roles, platform-partner processing, retention, access controls, audit trails, and whether oncology data leaves the lab or hospital environment. |
Check validation studies, endpoint definitions, patient population, scanner/site diversity, calibration, and whether evidence supports the actual treatment decision under consideration. |
Best used as a tumor-board or oncology decision-support input where pathologists and oncologists review the biomarker beside conventional pathology, ctDNA, and guideline-based factors. |
| Regard |
Treat as documentation, chart-review, and clinical-insight support; review any suspected-diagnosis or quality-capture workflow that affects diagnosis documentation, coding, or care decisions. |
Verify EHR data access, mobile recording, transcript retention, BAA terms, role-based access, audit logs, and whether scribe-app privacy terms differ from the contracted enterprise deployment. |
Require patient-record evidence for each recommended diagnosis, medication, history element, or documentation suggestion and monitor clinician acceptance alongside error and query rates. |
Best governed as physician-reviewed proactive documentation with explicit override, correction, coding, CDI, and quality-reporting handoffs. |
| Bayesian Health |
Treat the sepsis flagging workflow as high-risk medical-device software and match use to FDA 510(k) K250680; verify intended use, local policy, CDS review, and regulatory posture for any other Bayesian module. |
Do not rely on marketing-site privacy alone; require customer security documentation, BAA terms, EHR integration details, PHI retention, audit logs, access controls, and analytics-data boundaries. |
Review the FDA summary, peer-reviewed evidence, local validation, calibration, alert precision, sensitivity, adoption, equity monitoring, and whether outcome claims reproduce in comparable units. |
Best deployed with pathway owners, clinician education, response protocols, alert escalation rules, override tracking, and ongoing governance review. |
| CLEW ICU |
Treat as high-risk medical-device software and match deployment to the FDA-cleared indication, adult critical-care setting, prediction outputs, labeling, and change-control boundaries for K233216. |
Review EHR, bedside-device, tele-ICU, and cloud data flows; BAA terms; PHI retention; access controls; audit logs; security posture; support access; and whether privacy materials are website-only or customer-contract specific. |
Do not rely on clearance alone; validate local performance, alert thresholds, sensitivity, PPV, low-risk labeling, false negatives, false positives, workflow response, and subgroup performance. |
Best governed by ICU, tele-ICU, rapid-response, biomedical, informatics, and patient-safety owners with defined escalation rules, override review, downtime plans, and post-deployment monitoring. |
| Mednition KATE |
Treat as high-risk emergency-department clinical decision support; verify current FDA status for each KATE module because Breakthrough Device Designation can expedite review but does not by itself authorize marketing. |
Review customer-data privacy terms, BAA, EHR data feeds, free-text processing, PHI retention, audit logs, support access, analytics exports, and whether retrospective cohort searches create separate governance obligations. |
Validate published and vendor-stated triage and sepsis performance against local ED acuity mix, documentation quality, sepsis prevalence, nurse workflow, false alerts, missed alerts, and subgroup performance. |
Best governed as nurse-reviewed triage and sepsis-risk support with explicit escalation rules, alert documentation, override capture, quality review, downtime plans, and post-deployment monitoring. |
| Fathom |
Usually revenue-cycle automation rather than clinical decision support, but audit any workflow that directly assigns codes, affects claim submission, or changes coder accountability. |
Review BAA, HITRUST scope, EHR and billing-system integrations, data retention, access controls, audit logs, and whether customer data is used to tune automation. |
Validate automation rate, accuracy, denial impact, specialty coverage, low-confidence routing, and payer-rule behavior on local claims before reducing coder review. |
Best deployed with coder QA, exception queues, denial monitoring, and compliance review rather than blanket touchless submission. |
| CodaMetrix |
Primarily coding and revenue-cycle automation, but review service-line scope, coder accountability, payer compliance, and any autonomous coding claims before production use. |
Verify health-system data ingestion, Epic or EHR connection path, BAA terms, retention, audit trails, access controls, and whether longitudinal clinical context is reused for model improvement. |
Require service-line evidence for coding accuracy, denial reduction, turnaround time, ROI, payer-rule updates, and exception routing on local data. |
Best for enterprise coding teams that can stage automation by specialty, keep human review for exceptions, and monitor denials, audits, and coder workload. |
| Apicare AuthAdvisor |
Treat as high-risk payer utilization-management decision support because it can affect access to care; verify current CMS, state, accreditation, medical-policy, appeal, and adverse-determination requirements before automating any decision path. |
Review BAA terms, Datavant/Apixio contracting entity, PHI and administrative-data feeds, historical decision-data use, model-training boundaries, role-based access, audit logs, retention, and subcontractors. |
Require local validation for auto-approval precision, reviewer workload, overturned decisions, appeal rates, service-line performance, subgroup impact, and whether thresholds drift after policy or network changes. |
Best governed as payer prior authorization routing and approval support with configurable thresholds, clinical reviewer oversight, policy-change controls, denial safeguards, appeal monitoring, and provider/member communication checks. |
| Nym |
Treat Nym as revenue-cycle automation rather than clinical diagnosis support, while still reviewing coder accountability, payer compliance, claim submission controls, and any autonomous-release workflow that changes billing governance. |
Verify enterprise BAA terms, chart-data flows, EHR or Epic connectivity, SOC 2/HITRUST scope, HIPAA assessment details, retention, support access, audit logs, and model-improvement data use. |
Require service-line-specific validation on local encounters and track accuracy, denial rates, clean claims, audit trail completeness, exception rates, and the workload shift for coding staff. |
Best staged by specialty or facility, with confidence thresholds, exception queues, compliance sampling, denial monitoring, and rollback criteria before reducing human coding review. |
| SmarterDx |
Treat it as revenue integrity and documentation-support software; review any diagnosis, charge, or appeal recommendation that could affect coding, billing, quality reporting, or clinical documentation obligations. |
Do not rely on the public website privacy policy for PHI terms; verify the customer agreement, BAA, retention, access controls, audit logs, and any Smarter Technologies data-sharing path. |
Require chart-level evidence for every suggested diagnosis, charge, or appeal argument and monitor revenue lift alongside denial, audit, and compliance outcomes. |
Map how findings move from AI review into CDI, coding, physician query, denials, and claim workflows before expanding beyond a controlled pilot. |
| Waystar AltitudeAI |
Usually revenue cycle and administrative workflow software, but module-level review matters when outputs influence documentation specificity, coding, patient financial communication, or payer appeals. |
Verify BAA, platform security, patient communication consent, EHR and payer connectivity, role-based access, audit logs, and any data-network or AI-training terms for the chosen modules. |
Do not generalize platform-level claims; measure each module against local denial rates, reimbursement accuracy, patient AR, query response, coding accuracy, and compliance review outcomes. |
Start with a named revenue cycle workflow and define human approval, exception handling, writeback, payer communication, and reporting ownership before automating. |
| Cedar Intelligence |
Usually patient financial engagement and revenue cycle software, but review outreach, payment-plan, discount, financial-assistance, and support recommendations for consumer protection, consent, nondiscrimination, and payer/provider policy obligations. |
Verify PHI, payment, voice, SMS, portal, PCI, HIPAA, BAA, HITRUST, subcontractor, retention, audit-log, and model-improvement terms before enabling personalized billing journeys. |
Treat vendor lift and call-reduction metrics as directional; pilot against local patient AR, payment completion, complaint rates, assistance routing, call handle time, and resolution quality. |
Best governed with revenue cycle, compliance, patient experience, and call center ownership over approved messages, escalation paths, financial-assistance routing, and exception monitoring. |
| Carta Healthcare Voyager |
Primarily clinical data management and quality registry workflow software, but treat registry submission, quality reporting, research cohorting, and patient-care analytics as high-accountability outputs requiring local governance. |
Confirm dedicated deployment, FHIR scope, AWS Bedrock and model-vendor terms, BAA coverage, SOC 2 scope, encryption, retention, access controls, audit logs, and whether any data is reused for product improvement. |
Require field-level source evidence and compare AI-assisted abstraction against local abstractors for accuracy, IRR, missed data, hallucinated facts, and registry-specific edge cases. |
Best deployed as hybrid intelligence with named abstractor review, submission controls, exception queues, registry change management, and audit sampling before scaling. |
| Layer Health |
Treat as high-accountability chart-review and quality workflow support. Registry submission, clinical pathway, quality reporting, and research uses need workflow-specific governance and human validation. |
Do not rely on the website privacy policy for PHI handling; verify the customer agreement, BAA, source-system access, retention, model-provider terms, audit logs, and whether customer data trains or tunes models. |
Require field-level source evidence and compare outputs with local abstractors or clinical reviewers for accuracy, uncertainty handling, false inferences, and registry-specific definitions. |
Best deployed with named review owners, source-link review, exception queues, registry change management, quality-program signoff, and post-launch sampling before scaling to new use cases. |
| Wellsheet Care Team Copilot |
Treat as high-accountability EHR workflow, documentation, and clinical decision-support-adjacent software; review whether AI Pathways, calculators, discharge planning, or documentation outputs create regulated CDS or hospital policy obligations. |
Verify customer-specific BAA, API/FHIR access, EHR marketplace terms, PHI retention, support access, audit logs, role controls, and whether customer data can be used for model or product improvement. |
Require patient-chart source links for summaries, pathway suggestions, handoff content, discharge barriers, and documentation drafts, then compare outputs against local clinician review and quality measures. |
Best piloted in one inpatient workflow with named clinician owners, source-evidence review, exception queues, documentation signoff, pathway override capture, and post-launch monitoring. |
| Tennr |
Usually administrative patient-flow software, but review any workflow that influences patient prioritization, coverage criteria, authorization, or clinical documentation before automation. |
Verify the customer agreement, BAA, retention, de-identified data use, access controls, audit logs, and payer/provider communication channels before sending PHI. |
Require field-level evidence for extracted referral/order facts, missing-document decisions, payer criteria, and automated actions, then monitor denial and delay outcomes. |
Start with one referral or order workflow and define staff approval, exception handling, payer contact, patient contact, writeback, and escalation ownership. |
| AKASA |
Treat as revenue-cycle and documentation-integrity support; review any coding, CDI, quality, or authorization recommendation that can affect claims, payer communication, or clinical documentation. |
Confirm customer-specific model training, clinical and financial data access, EHR/API/EDI integrations, BAA, SOC 2/NIST/CIS scope, retention, audit logs, and reporting visibility. |
Validate evidence-backed recommendations, human expert review, local model tuning, prebill results, denial impact, and quality-reporting effects before scaling. |
Best deployed one workflow at a time with explicit review queues for coding, CDI, auth status, claim status, and revenue-cycle research outputs. |
| Forus |
Treat as medication-access and administrative automation; review payer-policy logic, appeal drafting, patient messaging, and any medication-specific recommendation boundary with compliance and prescribing leadership. |
Verify BAA coverage, SOC 2 documentation, EHR integration, patient communication consent, PHI retention, pharmacy or affordability-program sharing, audit logs, and subcontractor terms. |
Require traceable links between the prescription, chart evidence, payer criteria, generated forms, appeal content, and staff actions, then monitor approvals, delays, denials, renewals, and abandonment. |
Best piloted in one specialty medication workflow with staff approval for submissions, denials, appeals, patient updates, and pharmacy routing exceptions. |
| Case Health AI |
High-impact payer workflow software because outputs can influence medical necessity, approvals, denials, outreach, appeals, and CMS-0057-F implementation; require legal, clinical, compliance, and health-equity review. |
Confirm BAA/MSA scope, PHI fields, model-training permissions, audit logs, role access, encryption, retention, subprocessors, patient-rights handling, and whether plan data stays in the United States. |
Validate criteria matching, abstraction accuracy, denial rationales, incomplete-case routing, appeal outcomes, subgroup performance, and reviewer override data against real plan cases before production. |
Map each case path from intake through AI extraction, policy comparison, clinician review, automatic approval, denial routing, outreach, member/provider notice, and appeal evidence. |
| Notable |
Usually administrative automation, but review patient-access, quality, risk, prior-authorization, care-gap, and patient-message workflows for clinical, payer, and consent implications. |
Verify customer agreement and BAA terms rather than relying on website privacy language; check patient messaging consent, EHR access, automation logs, retention, and vendor subprocessors. |
Measure containment, booking accuracy, care-gap closure, authorization outcomes, no-show reduction, and exception quality against local baselines and patient-complaint data. |
Best governed through workflow-specific guardrails that route urgent needs, failed automations, billing disputes, and clinical questions back to staff. |
| Qventus |
Primarily operations automation, but review any workflow that changes patient prioritization, discharge timing, contact, or care coordination for clinical governance impact. |
The platform depends on EHR and operational data; verify BAA, security documentation, user permissions, patient-contact consent, and audit logging. |
Require local baselines and pilot metrics for capacity, throughput, cancellation reduction, follow-up completion, productivity, and exception handling. |
Map the exact action loop from prediction to staff task, patient contact, schedule change, EHR update, or escalation before automating. |
| Caremaze |
Treat as operational care-coordination support with patient-safety implications because discharge timing, placement, and outreach can affect care access and outcomes. |
Map EMR feeds, notes, patient identifiers, voice recordings or call transcripts, task logs, U.S. hosting, BAA terms, access controls, retention, and subprocessors before launch. |
Require local validation against discharge delay categories, disposition types, social-risk patterns, failed outreach, readmissions, and unintended access or equity effects. |
Best deployed with staff approval gates, clear task ownership, escalation paths, audit logs, discharge-policy review, and monitoring for automation failure or over-reliance. |
| Laudio |
Primarily operational workforce and patient-experience software, but review patient rounding, audit, compliance, staffing, and leader recommendations for employment, privacy, and care-quality governance impact. |
Verify workforce, patient-rounding, EHR, HRIS, timekeeping, communication, and analytics data flows plus access controls, retention, audit logs, security reports, and customer contract terms. |
Ask for comparable health-system evidence and monitor retention, engagement, manager capacity, patient-experience measures, staff burden, subgroup effects, and recommendation override behavior. |
Best governed as leader decision support with manager accountability, explicit escalation paths, workforce-policy review, and periodic checks that AI recommendations are useful and fair. |
| LeanTaaS iQueue |
Treat as operational capacity and scheduling decision support; review any configuration that affects patient prioritization, staffing, discharge timing, or access to care with clinical and operational governance. |
Verify customer agreement terms for EHR, scheduling, staffing, bed, infusion, and user data; public privacy language separates website data from customer-directed service data. |
Ask for workflow-specific evidence in comparable OR, infusion, or inpatient-flow settings and measure local utilization, access, delay, cancellation, overtime, and safety metrics before scaling. |
Map who sees each recommendation, who can override it, what can change automatically, and how exceptions are escalated during day-of operations. |
| Iodine AwareCDI |
Treat as CDI, coding, and revenue-cycle decision support; review any diagnosis, quality, or reimbursement recommendation that could affect claims, documentation, or payer communication. |
Confirm BAA terms, PHI access, aggregation or de-identification rights, EHR data flows, support access, audit logs, retention, and customer-specific service agreements. |
Require chart-level evidence for every suggested condition or query and monitor false positives, missed opportunities, denial outcomes, and physician response burden. |
Best deployed with CDI and coding review queues, clear query policies, appeal handoffs, and compliance auditing rather than automatic documentation changes. |
| Cohere Health |
Treat as payer operations and clinical-policy workflow software; review medical necessity, denial, appeal, CMS-0057 API, delegated review, and payment integrity obligations before production use. |
Verify customer BAA terms, PHI upload paths, access controls, encryption, retention, subcontractors, provider portal controls, and whether public website privacy terms differ from contracted platform terms. |
Ask for workflow-specific evidence on authorization accuracy, auto-approval quality, reviewer productivity, clinical guideline alignment, appeal outcomes, and provider/member impact in comparable specialties. |
Map the full loop from provider request to AI evidence extraction, policy comparison, clinician review, determination, provider communication, appeal, and downstream payment integrity monitoring. |
| Xsolis Dragonfly |
Treat as high-impact operations and clinical-policy workflow software because recommendations can affect medical necessity, admission status, concurrent authorization, denials, appeals, and care coordination. |
Verify PHI flows from EMR and financial systems, payer-provider data sharing, access controls, retention, audit logging, support access, customer BAA terms, and privacy-policy limitations. |
Require evidence for the exact utilization-management workflow and compare local outcomes for accuracy, denials, appeals, LOS, reviewer productivity, and unintended access or equity effects. |
Define which recommendations are advisory, which trigger reviewer queues, who signs off, how disagreements are handled, and how payer-provider collaboration is documented. |
| Navina |
Treat as clinical and revenue-adjacent decision support because outputs can influence chart review, diagnosis documentation, care gap closure, risk adjustment, quality reporting, and reimbursement. |
Verify the customer contract and BAA, EHR/HIE/claims data flows, scanned document handling, access logs, retention, support access, audit reports, and any model-improvement rights before using PHI. |
Require patient-level source links for every surfaced condition, care gap, HCC, summary, or documentation suggestion and validate performance on local primary-care and value-based populations. |
Best used with named clinician, coder, quality, and compliance review loops so AI-surfaced insights become auditable recommendations rather than automatic documentation changes. |
| Artisight |
Treat smart-room and ambient-monitoring use as high-accountability clinical operations infrastructure; review monitoring, documentation, alerting, device, and patient-safety obligations module by module. |
Map cameras, microphones, sensors, EHR links, room context, command-center views, recordings, retention, access controls, BAA terms, support access, and patient-notice obligations before go-live. |
Validate each workflow locally, especially fall prevention, virtual sitting, virtual nursing, OR throughput, voice documentation, alarm fatigue, response times, and safety-event review. |
Best deployed with named nursing, virtual care, IT, privacy, security, quality, and biomedical owners for room activation, escalation, downtime, review, and post-deployment monitoring. |
| care.ai |
Treat ambient monitoring and smart-room workflows as high-accountability clinical operations infrastructure; review device, video monitoring, alerting, patient-safety, and local regulatory obligations by workflow. |
Map camera, audio, sensor, room, EHR, command-center, and virtual-care data flows, then verify consent, patient notice, retention, access controls, support access, cybersecurity, BAA terms, and recording restrictions. |
Validate workflow-specific performance locally rather than relying on platform claims, especially for fall risk, patient deterioration, protocol adherence, alarm fatigue, staff response, and safety-event reduction. |
Best deployed with named nursing, virtual care, IT, privacy, security, biomedical, and quality owners for alert routing, escalation, downtime, review, and post-deployment monitoring. |
| AvaSure Intelligent Virtual Care |
Treat as high-accountability inpatient operations and patient-safety infrastructure; review each workflow separately because virtual nursing, observation, fall or elopement alerts, environmental sensing, and AI assistant functions can carry different device, clinical, labor, and patient-notice obligations. |
Map video, audio, room sensors, patient identifiers, EHR links, device feeds, command-center views, recordings, analytics, support access, hosting model, retention, access controls, privacy mode, BAA terms, and patient-notice requirements before activation. |
Validate AI-enabled observation and virtual nursing locally, measuring false alerts, missed events, observer ratio, response time, nursing burden, patient experience, incident reduction, subgroup effects, and whether analytics match the deployed workflow. |
Best governed with named nursing, virtual care, patient safety, IT, security, privacy, biomedical, and quality owners for room activation, escalation, handoff, downtime, audit review, and post-deployment monitoring. |
| Caregility Connected Care |
Treat as high-accountability inpatient operations and patient-safety infrastructure; review each module separately because telehealth, observation, contactless vitals, voice workflows, and AI alerts can carry different clinical, device, labor, and patient-notice obligations. |
Map video, audio, radar, vitals, patient identifiers, room context, telehealth sessions, EHR links, recordings, analytics, support access, retention, access controls, BAA terms, and patient-notice requirements before activation. |
Validate each deployed workflow locally rather than relying on platform claims, especially virtual nursing, sitter ratios, fall or elopement detection, vitals trends, response times, missed events, false alerts, and staff burden. |
Best governed with named nursing, virtual care, patient safety, IT, security, privacy, biomedical, and quality owners for room activation, escalation, handoff, downtime, audit review, and post-deployment monitoring. |
| Oxehealth Oxevision |
Separate Sleep, Vital Signs, Activity Tracker, Seclusion, and local observation workflows because FDA, UK/EU device status, CDSS status, version, and intended use can differ by module. |
Map camera/infrared data, live-view windows, clear-video requests, room context, reports, retention, access controls, patient notices, consent, ward policy, and support access before go-live. |
Validate the product in the target ward type and patient population, measuring false alerts, missed events, observation burden, nighttime disturbance, patient dignity, and incident-review quality. |
Best governed as supervised nursing and safety support, with trained users, explicit escalation rules, downtime plans, patient communication, and governance review of each ward deployment. |
| Cadence Clinical Intelligence |
Treat as high-impact remote care delivery and clinical operations support; review physician control, medication titration, remote monitoring, care-management, billing, and state-practice obligations before launch. |
Review Cadence privacy materials, provider Notices of Privacy Practices, device and EHR integrations, patient consent, access controls, retention, support access, and customer or partner agreements for PHI handling. |
Use Cadence's public outcome and publication claims as a starting point, then validate alert performance, medication workflow, utilization impact, rural or underserved reach, and adverse-event review locally. |
Best governed as clinician-led remote care infrastructure with explicit protocols for AI-agent suggestions, nurse or clinician escalation, medication changes, device failures, and patient nonresponse. |
| Biofourmis Biovitals |
Verify the exact Biovitals product, version, device configuration, intended use, country, and FDA or local authorization before treating analytics as clinical monitoring support. |
Review Biofourmis privacy materials and customer agreements for PHI, cloud storage, cross-border transfer, device data, retention, audit logging, support access, and whether HIPAA notices govern patient data. |
Validate personalized baseline and deviation logic on the local care pathway, sensor mix, acuity level, adherence pattern, and escalation capacity rather than relying only on platform claims. |
Best governed with explicit clinical review, alert triage, device troubleshooting, patient outreach, escalation ownership, downtime plans, and post-deployment safety monitoring. |
| Current Health |
Treat as remote monitoring and care-at-home infrastructure; verify whether any module changes clinical triage, patient prioritization, alarm routing, reimbursement, or device-regulated responsibilities. |
Review Current Health patient privacy terms, customer agreements, healthcare-organization notices, device data, questionnaire data, cloud analytics, retention, support access, and EHR integration controls. |
Measure local reliability, adherence, alarm quality, response time, readmission or utilization impact, patient experience, and staff burden before scaling monitoring pathways. |
Best governed through care-at-home playbooks that define device onboarding, alarm triage, nurse review, escalation, tech support, downtime, and discharge from monitoring. |
| Huma Cloud Platform |
Classify each Huma-built application separately because platform, RPM, triage, clinical dashboard, research, and SaMD workflows can carry different intended-use and jurisdiction requirements. |
Review Huma documentation and contract terms for patient data settings, consent, access controls, integrations, device data, retention, export, subprocessors, and regional hosting before deployment. |
Require pathway-specific validation for triage, RPM, screening, clinical dashboard, or research workflows; platform scale does not prove local clinical safety or performance. |
Best governed as configurable infrastructure with named product, clinical, privacy, security, and safety owners for every app built, changed, monitored, and retired. |
| John Snow Labs Healthcare NLP |
Treat as clinical data infrastructure and workflow support unless a configured pipeline directly informs care, diagnosis, or regulated medical-device use; classify each deployment by intended use and jurisdiction. |
Review license terms, BAA, hosting model, de-identification workflow, PHI categories, prompt and output handling, support access, audit logs, retention, and whether sample/demo data are used to improve models. |
Validate extraction, assertion, terminology mapping, summarization, OCR, and de-identification performance on local notes, scanned documents, specialty language, rare entities, and downstream registry or analytics definitions. |
Best governed as a reviewed data-curation layer with quality sampling, exception queues, privacy approval, reviewer signoff, and change control before scaling to new document types or downstream analytics. |
| Hippocratic AI |
Start by confirming whether the planned agent is access, follow-up, RPM adherence, inpatient nurse support, life-sciences, or clinical conversation support; reclassify if local configuration influences diagnosis, prescribing, triage, medication decisions, or care escalation. |
Do not infer deployment PHI terms from public website privacy language alone; verify the customer contract, BAA, call recording and transcript handling, de-identification, retention, model-improvement rights, support access, and subcontractors for the exact workflow. |
Treat vendor safety counts, benchmark claims, and de-identified call examples as directional; require local scripts, adversarial cases, escalation audits, patient-experience metrics, nurse-review results, equity checks, and post-launch incident review. |
Constrain each agent to named intents, approved scripts, handoff rules, emergency escalation, exclusions, monitoring dashboards, and accountable owners before exposing it to patients or inpatient teams. |
| Tucuvi |
Treat as high-accountability patient-facing clinical workflow software; verify the CE-marked SaMD scope, intended use, jurisdiction, clinical protocol, and whether each deployment is monitoring, scheduling, documentation, or triage-like support. |
Review consent capture, call recording, transcripts, health data, PHI, HIPAA/GDPR terms, regional data location, subprocessors, access controls, retention, deletion, and controller/processor roles before activating patient calls. |
Use vendor case studies as directional only; require local testing of alert accuracy, missed deterioration, false escalation, call completion, language performance, patient comprehension, and nurse-review burden. |
Deploy with named clinical, nursing, patient-access, privacy, security, and integration owners for protocol design, anomaly review, urgent escalation, downtime handling, and post-deployment monitoring. |
| Infermedica |
Separate the hosted product from the Engine API: Infermedica says the Engine API itself is not intended for direct clinical use and that final device classification depends on the customer-built application and jurisdiction. |
The docs say Engine API processes de-identified symptom sets while Platform API can store personal data; verify which mode you are buying, whether anonymous mode is enabled, and how retention and access are handled contractually. |
Do not rely on global accuracy or validation claims alone; test triage disposition, language performance, symptom coverage, and false reassurance risk in your local population and care-routing setup. |
Decide whether the product is being used for intake, symptom checking, triage, or nurse-support, then define emergency scripts, escalation paths, and who owns the final recommendation. |
| Ubie |
Treat as high-risk patient-facing symptom assessment; confirm jurisdiction, intended use, labeling, and whether the deployment changes care-routing or regulated-device obligations. |
Review Ubie's collection of health inputs, medication and appointment information, account data, analytics, transfers, retention, and any enterprise agreement before directing patients to it. |
Validate triage, possible-cause, and red-flag behavior against local protocols and population needs rather than relying only on global accuracy or publication-count claims. |
Use only with clear warnings, emergency instructions, escalation paths, and a plan for how patients move from self-check output to appropriate care. |
| Hyro |
Treat Hyro as patient-access infrastructure unless the configured agent starts handling symptoms, medication questions, or clinical guidance that could change the regulatory and clinical accountability profile. |
Verify the actual healthcare deployment terms for PHI, patient record access, recordings, SMS or chat retention, Epic or CRM integrations, and any BAA or customer-specific privacy obligations. |
Vendor accuracy and ROI claims should be treated as case-study signals only; measure automation, abandonment, handoff quality, incorrect routing, and unsafe-answer rates on your own intents before scaling. |
Define exactly which requests are auto-resolved, which are routed, and which require staff takeover so the agent stays within approved access and support boundaries. |
| Infinitus |
Treat as healthcare communications and access workflow automation; reassess risk when agents collect symptoms, side effects, adverse events, financial eligibility, or payer denial details that require regulated or staffed follow-up. |
Review consent, call recording, transcripts, PHI, identity verification, retention, subprocessors, customer contracts, and BAA coverage before deploying agents into patient, payor, or provider calls. |
Validate call-completion, data accuracy, protocol compliance, adverse-event detection, handoff quality, and patient experience on your own call types instead of relying on aggregate platform claims. |
Define each call script, forbidden statements, escalation trigger, staff queue, retry behavior, documentation destination, and monitoring owner before scaling agentic calls. |
| Artera Harmony |
Treat as patient access and communications infrastructure unless a configured workflow collects symptoms, provides triage-like guidance, or changes clinical escalation. |
Review PHI handling, secure versus unsecure channels, consent, retention, EHR/vendor integrations, message content, role access, and provider-specific privacy responsibilities. |
Measure no-show, scheduling, intake, billing, response, and staff-time outcomes separately, and test edge cases before adding autonomous voice or text agents. |
Map every message source, cadence, channel, escalation path, and staff queue so AI automation does not create duplicate, conflicting, or unsafe patient communications. |
| Fabric |
Separate administrative access workflows from symptom gathering, triage, and virtual care, because physician-built clinical logic and routing can carry a different clinical-governance and device-review burden than scheduling alone. |
Fabric publishes HIPAA and SOC 2 Type 2 positioning, but you still need the customer contract, access-control design, retention terms, integration boundaries, and patient-consent model for the exact deployment. |
Use case studies as a starting point only; validate routing accuracy, symptom-intake safety, scheduling completion, handoff quality, and downstream clinical or access outcomes in your own setting. |
Map where symptom collection ends, where routing or virtual care begins, and when a human clinician or access team member must review or take over. |
| Corti |
Risk depends on the configured Corti workflow, so separate documentation, coding, prior authorization, and patient-facing agent use before deciding what clinical-governance or regulatory review is required. |
Verify regional hosting, PHI retention, voice and transcript controls, subcontractors, customer logging boundaries, and BAA or DPA terms for the specific deployment rather than relying on generic platform claims. |
Treat benchmark and launch claims as a starting point only; run workflow-specific tests for escalation, hallucinations, multilingual quality, coding accuracy, and human override burden before production use. |
Constrain each agent, model, and tool path to a named job with auditability, handoff rules, and rollback paths so governed deployment remains practical. |
| Sully.ai |
Risk varies sharply by agent role; distinguish documentation support, coding extraction, receptionist workflows, triage, and any clinical-advice behavior before deployment. |
Verify HIPAA/BAA terms, audio and transcript retention, webhook security, API logging, EHR writeback controls, and subcontractor access. |
Do not rely on broad benchmark or marketing claims alone; run role-specific safety tests for notes, coding, patient contact, and escalation. |
Constrain each agent to a named job with handoff rules, clinician or staff review, rollback paths, and monitoring before broad rollout. |
| Memora Health |
Separate care management, education, symptom collection, remote monitoring, and escalation workflows because patient-facing risk changes by program and message content. |
Review SMS consent, PHI in text channels, account and profile retention, subcontractors, customer-contract terms, BAA coverage, opt-out controls, and how any Commure transition affects data governance. |
Validate engagement, adherence, symptom escalation, patient satisfaction, and safety outcomes in the specific care program rather than relying on cross-program performance claims. |
Best governed as care-team extension software with defined message libraries, escalation paths, queue ownership, after-hours behavior, and clinical review for program updates. |
| Ada Health |
Confirm which Ada product and geography are in scope, because Ada positions some enterprise flows as regulated symptom-assessment technology and says jurisdiction-specific limits still need to be verified. |
Ada publishes privacy and compliance claims, but the deployment review still needs to cover consent, partner data sharing, retention, automated-decision boundaries, and any HIPAA or regional health-data obligations. |
Use published studies and enterprise claims as supporting context only; validate routing accuracy, false reassurance risk, escalation quality, and handover usefulness in your own population and service map. |
Define how symptom assessment, care navigation, and clinician or access-team handover connect so users are not left with ambiguous next steps or delayed escalation. |
| Mediktor |
Separate symptom assessment, routing, telemedicine support, and LLM-enhanced agent behavior because each deployment can change clinical, regional, and regulated-device obligations. |
Review privacy, security, consent, retention, subprocessor, integration, and customer-contract terms before using Mediktor with PHI or patient-identifiable symptom data. |
Ask for clinical-validation materials that match the target language, patient population, care setting, acuity distribution, and routing protocol. |
Configure it as a bounded digital-front-door workflow with clear service routing, emergency escalation, human handoff, and post-launch safety review. |
| Luma Health Navigator |
Treat as patient access and operational automation unless a configured workflow starts making clinical recommendations, handling urgent symptoms, or changing medication/refill decisions. |
Review Luma's policy documents, AI data handling claims, voice/SMS data flows, EHR integrations, subprocessors, retention, access controls, and BAA terms for the exact Navigator workflow. |
Use public customer outcomes as directional only; validate call automation, patient verification, cancellation accuracy, refill routing, escalation quality, language performance, and safety edge cases locally. |
Define each self-service task, fallback path, staff queue, channel switch, patient-identity check, and monitoring owner before letting Navigator resolve patient requests autonomously. |
| Clearstep Smart Care Routing |
Treat as high-risk patient-facing triage and routing; verify intended use, jurisdiction, protocol ownership, clinical-review process, and whether the deployment creates regulated medical-device obligations. |
Review BAA coverage, transcript and symptom-data retention, AWS hosting, encryption, identity handling, email limitations, EHR/CRM integrations, and customer-controller responsibilities before launch. |
Validate triage dispositions, emergency handling, endpoint fit, false reassurance, over-triage, and patient completion in the local service map and acuity mix. |
Deploy with explicit care endpoints, emergency scripts, staff escalation queues, scheduling rules, marketing boundaries, and post-launch review of unexpected triage patterns. |
| Canary Speech |
Treat as high-risk screening or clinical decision-support software unless the exact deployment is limited to non-clinical wellness. Verify intended use, condition claims, region, and whether any medical-device or clinical validation obligations apply. |
Review audio collection, voice recordings, transcripts, derived voice features, consent, BAA/DPA coverage, retention, model-improvement use, de-identification, security certifications, and call-center or API data flows. |
Require condition-specific validation for the intended population, language, environment, microphone, and clinical workflow; inspect sensitivity, specificity, calibration, bias, and peer-reviewed or technical-report evidence. |
Best governed as clinician-reviewed screening or monitoring support with explicit escalation, crisis routing, score interpretation guidance, and post-launch monitoring rather than as autonomous diagnosis. |
| Ellipsis Health |
Treat as high-risk behavioral-health screening and clinical decision-support software unless a deployment is explicitly limited to non-clinical wellness or research. Verify intended use, jurisdiction, claims, and whether medical-device obligations apply. |
Review audio capture, voiceprint sensitivity, transcripts, derived features, consent, deletion rights, BAA/DPA coverage, retention, model-training boundaries, subcontractors, and telehealth or call-center data flows. |
Require condition-specific validation for the deployment population, language, phone or microphone channel, care setting, and workflow; inspect calibration, bias, sensitivity, specificity, and clinical follow-up results. |
Best governed as clinician- or care-manager-reviewed screening support with documented escalation, crisis routing, score interpretation guidance, and post-launch safety monitoring. |
| Syllable Healthcare Agents |
Treat as access and workflow automation unless an agent is configured for symptoms, clinical guidance, or autonomous EHR actions that require clinical-governance and regulatory review. |
Verify BAA terms, Epic authorization scope, transcript retention, third-party model routing, speech vendor routing, logs, role access, and audit evidence for the exact channels and agents. |
Run scripted and live-shadow tests for scheduling accuracy, patient verification, handoff quality, latency, tool failures, speech recognition, and unsafe or out-of-scope responses. |
Limit each agent to named intents, approved tools, identity checks, escalation rules, and monitoring dashboards before expanding to additional access-center workflows. |
| Assort Health |
Treat as patient access and operational automation unless a configured workflow handles symptoms, care routing, refills, or clinical questions that need clinical governance and escalation review. |
Verify BAA terms, patient privacy policy scope, call recording and transcript retention, SMS/email consent, EHR/PMS permissions, deidentified-data use, and subcontractor/model terms. |
Validate booking accuracy, escalation quality, specialty-protocol adherence, abandonment reduction, patient satisfaction, care-gap completion, and payment workflows against local call recordings and staff audits. |
Start with named intents and approved scripts, then define identity checks, forbidden advice, staff handoff, EHR writeback, QA sampling, and stop rules before expanding to more complex calls. |
| Anima Health |
Treat as high-accountability patient-access and primary-care workflow software. Verify exact module scope, MHRA Class I status where applicable, NHS clinical-safety documentation, local DCB0160 deployment duties, and whether configured workflows cross into clinical triage or decision support. |
Review DPA, DPIA templates, UK GDPR controller/processor roles, patient identifiers, message and document content, video-call metadata, SMS suppliers, UK hosting, staff access, retention, EHR integration permissions, and whether any AI or ambient-scribe processing changes the data-flow map. |
Use vendor claims and practice testimonials as directional only; measure local demand management, response time, routing accuracy, document-processing errors, code-suggestion quality, unsafe request handling, accessibility, complaints, and clinician workload. |
Deploy with named GP, nursing, admin, clinical-safety, IG, and integration owners; define approved request categories, red-flag escalation, inbox ownership, EHR writeback review, scribe signoff, downtime plans, and post-launch audit cadence. |
| Limbic Access |
Treat as high-risk patient-facing mental health intake and clinical decision-support software; verify UKCA status, IFU, NICE evidence-generation conditions, local DTAC or equivalent approvals, age limits, and whether diagnosis-predictor functions are in scope. |
Review consent, mental health data handling, dashboard access, EHR integration, privacy-policy region, retention, safety notices, support access, subcontractors, and service-provider information-governance controls before launch. |
Use NICE's evidence-generation requirements as a minimum: track information quality, clinical-assessment impact, administrative burden, time saved, patient feedback, costs, equality, and local safety events. |
Best governed as a digital front door that prepares clinician-led mental health assessments, with clear emergency routing, excluded-use rules, human review of reports, and post-launch monitoring. |
| Wysa |
Treat as high-risk behavioral-health software. Verify the exact product, intended use, population, geography, clinical-program status, and whether any FDA Breakthrough designation has progressed to clearance or authorization for the planned deployment. |
Review conversation data, assessment scores, safety flags, institution reporting, OpenAI/LLM processing, anonymized training and analytics, AWS hosting, fitness-data use, coach or medical-assistant records, and local BAA/DPA terms. |
Review product-specific clinical evidence, crisis and safeguarding performance, PHQ-9/GAD-7 handling, user engagement, human escalation quality, and outcomes for the target population before rollout. |
Best governed as supervised behavioral-health access and support, with clear exclusions, emergency routing, human escalation, institution reporting boundaries, and periodic clinical safety review. |
| Woebot Health |
Treat as high-risk behavioral-health software. Breakthrough Device Designation for WB001 is not the same as FDA clearance, and Woebot's own AI principles page identifies W-DISC-MVP as investigational and not FDA evaluated, cleared, or approved. |
Review privacy policy, PHI handling, HIPAA posture, partner data sharing, third-party model or service-provider use, data retention, user rights, and whether organization-specific BAA or DPA terms cover the planned workflow. |
Separate broad wellness claims from product-specific evidence. Require current trial status, peer-reviewed publications, safety data, population fit, crisis-performance evidence, and outcome measures for the exact product version. |
Govern as supplemental mental-health support or clinician-supervised digital-therapeutic access, with explicit crisis routing, excluded-use rules, partner responsibilities, human escalation, and incident review. |
| K Health |
Treat as high-risk patient-facing clinical AI and virtual care access. Verify intended use, clinician involvement, regional medical-practice structure, symptom-checker limitations, and whether any configured workflow creates regulated medical-device obligations. |
Review HIPAA/OHCA coverage after account creation, consumer health data notice, AI model-improvement terms, advertising and analytics sharing, partner health-system records, identity verification, and data retention. |
Check peer-reviewed and internal validation claims against the exact workflow, acuity mix, patient population, clinician review process, and downstream prescription or referral decisions. |
Best governed as AI-assisted intake and access with licensed clinician review, explicit emergency exclusions, clear patient messaging, partner-health-system continuity, and monitoring of unsafe dispositions. |
| MedAware |
Treat as high-risk medication clinical decision support; confirm intended use, jurisdiction, and whether the deployed claims or partner integration create regulated software obligations. |
Review EHR and prescribing-data access, PHI flow, partner environment controls, BAA terms, audit logs, data retention, and whether local data are used for model refinement. |
Validate alert relevance, false positives, missed high-risk orders, clinician behavior change, medication-error outcomes, and subgroup performance in local medication workflows. |
Best deployed with pharmacy, informatics, medication safety, prescriber governance, and monitored escalation paths rather than unfiltered alerts to frontline clinicians. |
| DrFirst Clinical-Grade AI |
Treat as medication safety and reconciliation decision support; verify intended use, EHR integration, safety-check claims, and whether any deployed workflow requires clinical, legal, or regulated software review. |
Review prescription, payer, medication-history, EHR, support, and integration data flows plus BAA terms, audit logs, role access, retention, and any AI training or model-improvement rights. |
Validate sig translation, inferred detail safety, medication-history completeness, allergy or interaction alert triggering, false normalization, and downstream medication-error outcomes locally. |
Best deployed with pharmacy and clinical informatics ownership, reconciliation review, exception queues for low-confidence data, and monitoring of overrides or missed medication risks. |
| DoseMeRx |
Treat as high-risk medication dosing decision support and verify local clearance, intended use, drug-model scope, and clinician accountability before production use. |
Review patient demographics, lab data, medication levels, genotype fields, EHR integration, hosting, HITRUST evidence, BAA terms, retention, and access controls. |
Validate drug-model fit, lab-timing assumptions, local patient mix, outcome claims, and dosing recommendations against stewardship or pharmacy protocols. |
Best used inside pharmacist-led dosing programs with documented review, lab-quality checks, escalation rules, and dose-change signoff. |
| InsightRX Nova |
Treat as high-risk precision dosing clinical decision support; verify exact regulatory, quality, and intended-use claims for the deployment country and workflow. |
Review EHR, lab, dosing, demographics, and life-sciences data flows plus security certifications, access controls, BAA or DPA terms, retention, and auditability. |
Validate model implementation, local drug-level timing, uncertainty, drug-library fit, and outcome monitoring before changing dosing protocols. |
Best used with clinical pharmacy or pharmacology ownership, protocol alignment, dose-review documentation, lab coordination, and ongoing model-performance review. |
| Arine |
Treat as medication management and population-health decision support unless configured for direct clinical decisions; align use with pharmacist, care-team, quality, and plan obligations. |
Review claims, pharmacy, clinical, SDoH, outreach, language, and member-contact data flows plus BAAs, consent posture, subcontractors, retention, and audit controls. |
Validate program-level outcomes, recommendation acceptance, adherence and hospitalization claims, subgroup performance, and causal assumptions against local or plan data. |
Best used with pharmacist and care-team review, defined outreach scripts, prescriber engagement rules, quality-measure ownership, and continuous monitoring. |
| Bluesight Prism |
Treat as pharmacy operations and compliance decision support, not a final determination engine; diversion investigations require policy, HR, legal, and clinical governance. |
Review controlled-substance, PHI, employee, audit, prompt, and model-provider data handling plus BAA terms, role permissions, retention, and investigation access controls. |
Validate that summaries trace back to source records, preserve context, avoid unsupported accusations, and improve review time without increasing false escalations. |
Best deployed with compliance-approved prompts, investigation checklists, source-record review, escalation rules, and periodic audit of AI-assisted findings. |
| EveryDose Provider |
Treat as medication management, adherence, education, and remote monitoring support unless configured for clinical decision support; medication decisions remain with licensed staff. |
Review patient app, provider portal, EHR, claims, pharmacy, survey, outreach, and analytics data flows plus BAA terms, hosting, encryption, access, retention, and audit controls. |
Validate adherence, med-list accuracy, adverse-event surveillance, readmission, quality-measure, patient satisfaction, and workload claims against local populations and workflows. |
Best used with defined outreach queues, medication-concern escalation, pharmacist or clinician review, patient education ownership, and EHR documentation rules. |
| DreaMed endo.digital |
Treat as high-risk, regulated diabetes clinical decision support. Verify the exact cleared device version, indications, patient population, insulin regimen, device compatibility, and clinician-review requirements before use. |
Review diabetes device data, patient app data, EHR integration, PHI, audit logs, SOC 2 and HIPAA claims, BAA terms, retention, support access, and any data use for product improvement. |
Validate FDA summaries, clinical evidence, local patient mix, unsupported-regimen exclusions, clinician agreement, override rates, glycemic outcomes, and adverse-event monitoring. |
Best deployed with endocrinology and pharmacy governance, clear insulin-change signoff, device-data quality checks, remote-monitoring protocols, and documentation of accepted or rejected recommendations. |
| GenXys TreatGx |
Treat as pharmacogenomic clinical decision support and verify local CDS, laboratory, privacy, and prescribing obligations for the intended use and jurisdiction. |
Review genomic, medication, condition, allergy, EHR, pharmacy, lab, and user-action data flows plus BAA terms, hosting, access, retention, and auditability. |
Validate source-guideline currency, PGx phenotype handling, interaction prioritization, condition coverage, alert burden, and recommendation acceptance in local pilots. |
Best governed through prescriber, pharmacist, informatics, lab, and precision medicine review with explicit responsibility for final prescribing decisions. |
| FDB Meducation |
Treat as medication education and adherence support unless local configuration turns it into medication decision support; validate instructions before patient-facing use. |
Review EHR, pharmacy, MAR, portal, print, and language-preference data flows plus BAA/license terms, access, retention, and patient-delivery controls. |
Check readability, translation quality, patient comprehension, medication-error reduction, adherence outcomes, and validation of AI/NLP-transformed sig instructions. |
Best used as a clinician-reviewed education layer embedded in discharge, MAR, pharmacy, or ambulatory workflows with counseling and escalation still owned by staff. |
| AiCure |
Treat as medication adherence, trial monitoring, and patient engagement support; verify whether the local use affects clinical trial endpoints, regulated evidence generation, remote patient monitoring, or patient-care decisions. |
Review captured video, facial images, biometric matching, medication-event data, PHI, sponsor/provider access, retention, encrypted storage, country filings, consent, and child or vulnerable-population notices before use. |
Validate adherence detection, missed-dose alerts, participant burden, equity across devices and populations, site intervention timing, and how adherence data changes trial or care decisions. |
Best governed with study-team or care-team review queues, participant support scripts, escalation paths, consent language, data-monitoring plans, and audit trails for every adherence intervention. |
| Medisafe Maestro |
Treat as medication adherence and patient engagement support; verify whether local configuration triggers adverse-event reporting, regulated patient support, remote monitoring, or clinical program obligations. |
Review medication lists, health information, caregiver contacts, app telemetry, voice interactions, pharma and provider data sharing, AI insight generation, consent, retention, and patient rights. |
Validate adherence and persistence outcomes by therapy, population, channel, and language, and test false-positive or overmessaging risk before scaling. |
Best governed with approved patient-support content, documented escalation paths, adverse-event intake rules, program analytics review, and clinician or pharmacist ownership for medication decisions. |
| Synapse Medication Shield |
Verify the exact module and jurisdiction because Synapse materials reference pharmacovigilance automation, e-prescribing, CE-marked medical-device components, HAS certification, and ONC-certified Synapse Prescribe disclosures. |
Review anonymization, HDS hosting, GDPR posture, PHI export, adverse-event report content, patient identifiers, integration logs, retention, and cross-border transfer constraints. |
Check published validation of adverse-event coding, local MedDRA mapping performance, severity prioritization, expert override rates, and downstream reporting quality. |
Best governed as expert-reviewed pharmacovigilance or prescribing-safety support with clear queues, override documentation, regulatory reporting ownership, and post-deployment performance monitoring. |
| RxLogix PV Signal |
Treat as regulated life-sciences pharmacovigilance infrastructure; validate against GxP, FDA, EMA, local authority, SOP, inspection, and safety reporting requirements before production use. |
Review safety case data, adverse-event narratives, patient identifiers, reporter information, literature and database connectors, role access, audit logs, hosting model, and cross-border processing. |
Evaluate signal detection sensitivity, false positives, literature mining quality, data-source coverage, validation workflow, audit evidence, and safety physician acceptance before relying on automation. |
Best governed as a PV operations platform with safety expert review, SOP-aligned signal lifecycle states, documented decisions, inspection-ready audit trails, and periodic model and data-source review. |
| ArisGlobal LifeSphere Safety |
Treat as regulated pharmacovigilance infrastructure; confirm GxP validation, local health-authority reporting obligations, SOP alignment, and module-specific intended use before production automation. |
Review safety narratives, patient and reporter identifiers, multilingual intake, email or document ingestion, literature feeds, translation flows, role access, audit logs, vendor support, retention, and cross-border transfers. |
Validate extraction accuracy, duplicate handling, MedDRA or WHODrug coding support, signal quality, translation quality, false negatives, false positives, and reviewer acceptance against local case data. |
Best governed as safety expert-reviewed automation with documented queues, exception handling, manual fallback, versioned SOPs, inspection-ready audit evidence, and ongoing PV quality monitoring. |
| Oracle Safety One Argus |
Treat as life-sciences safety and regulatory reporting infrastructure; validate configuration, reporting rules, records controls, and SOPs against FDA, EMA, ICH, and local authority requirements. |
Review adverse-event source documents, patient and reporter identifiers, attachments, partner distributions, gateway submissions, audit logs, role access, hosting model, and retention. |
Pilot extraction, duplicate detection, coding, workflow prioritization, case quality, reporting timeliness, false-negative risk, and user override patterns against representative safety cases. |
Best deployed with clear case-owner responsibilities, medical review checkpoints, regulatory submission controls, validation evidence, manual fallback, and periodic PV quality review. |
| IQVIA Vigilance Detect |
Treat as safety intake and PV operations infrastructure; confirm validation, SOP alignment, inspection support, and regional reporting obligations before using automation in production. |
Review call recordings, emails, documents, chats, patient and reporter identifiers, product complaint data, translations, service access, hosting, retention, and cross-border transfer controls. |
Measure extraction sensitivity, field-level accuracy, missed adverse events, seriousness classification, language performance, duplicate handling, follow-up burden, and reviewer acceptance locally. |
Best governed as intake acceleration with source-linked review queues, low-confidence escalation, quality sampling, medical review boundaries, and documented overrides. |
| Veeva Vault Safety AI |
Treat as pharmacovigilance system-of-record infrastructure; validate against GxP, ICH, FDA, EMA, local authority, sponsor oversight, and outsourced PV process requirements. |
Review adverse-event case data, patient and reporter identifiers, attachments, partner distributions, safety documents, signal workspaces, AI processing, role access, retention, and support access. |
Validate automation accuracy, case quality, submission timeliness, signal workflow quality, documentation control, user overrides, and inspection evidence with representative safety operations. |
Best governed with sponsor and CRO role clarity, SOP-aligned queues, medical review checkpoints, controlled signal decisions, audit exports, and periodic quality monitoring. |
| Prenosis Sepsis ImmunoScore |
Treat as prescription AI/ML-based medical-device software and match use to FDA De Novo DEN230036, including suspected sepsis context, adult ED or hospital patients, blood-culture workflow, and clinician-review requirements. |
Review EHR, lab, biomarker, and cloud algorithm-suite data flows; PHI transfer; retention; access controls; security certifications; audit logs; and BAA or data-processing terms before production use. |
Validate local performance against sepsis prevalence, laboratory workflows, demographics, comorbidities, SEP-1 objectives, false-positive burden, and missed-sepsis risk rather than relying on authorization alone. |
Best governed through emergency medicine, hospital medicine, infectious disease, nursing, lab, quality, and informatics teams with clear escalation, override, monitoring, and downtime procedures. |
| Anumana ECG-AI |
Match each deployment to the exact cleared algorithm and intended use, including K232699 for low ejection fraction and K252360 for pulmonary hypertension; do not generalize clearance across future or investigational cardiac conditions. |
Review ECG, EHR, result-routing, audit-log, customer-support, and integration data flows; Anumana says the pulmonary hypertension algorithm runs within the health-system environment, but contract and architecture review still matter. |
Evaluate local performance by ECG source, patient mix, prevalence, care setting, downstream echo or referral pathway, false-positive burden, and whether published sensitivity and specificity match the intended workflow. |
Best governed as clinician-reviewed cardiac detection support with defined ECG-system integration, result display, referral criteria, cardiology escalation, monitoring, and patient communication rules. |
| Eko Health SENSORA |
Treat as regulated cardiac detection support tied to specific Eko devices, algorithms, adult-use labeling, and FDA-cleared indications; do not generalize one algorithm clearance to unsupported arrhythmias, pediatric workflows, diagnosis, or treatment decisions. |
Review ECG, phonocardiogram, audio, patient identifier, app, dashboard, EHR, support, and analytics data flows, plus BAA, HIPAA, encryption, access control, retention, deletion, and secondary-use terms. |
Check FDA records, Eko's clinical-study references, algorithm-specific validation, acquisition protocol, patient mix, structural murmur and AFib performance, low-EF evidence, false-positive burden, and whether results match local screening goals. |
Best governed as clinician-reviewed point-of-care cardiac screening support with trained acquisition staff, documented provider over-read, clear referral thresholds, conventional diagnostic backup, and monitoring for over-referral or missed disease. |
| AliveCor Kardia 12L |
Treat as regulated ECG hardware and algorithmic cardiac interpretation support; match use to the current FDA-cleared Kardia 12L and KAI 12L labeling rather than broad AliveCor or Kardia device claims. |
Review device, app, KardiaPro, API, cloud, NPI, patient-profile, ECG recording, support, and telehealth data flows, plus BAA, HIPAA, SOC 2, ISO 27001, HITRUST, retention, and deletion terms. |
Check FDA clearance materials, IFU limits, validation population, operator workflow, comparison with conventional 12-lead ECG, false positives, false negatives, and local follow-up outcomes. |
Best governed as clinician-reviewed ECG acquisition and interpretation support with trained operators, clear escalation pathways, conventional ECG backup, cardiology review, and monitoring for over-reliance. |
| Philips Cardiologs Holter |
Match the deployment to the exact Cardiologs Holter Platform or Philips Holter Analysis System record, including K250569 for Cardiologs Holter Platform and K241890 for Philips Holter Analysis System, plus geography, patient-age, ECG-source, and intended-use limits. |
Review cloud hosting, ECG upload, API integration, ECG management-system transfers, patient identifiers, report exports, audit logs, technician and physician access, support access, data residency, retention, deletion, BAA, HIPAA, and GDPR terms. |
Validate arrhythmia detection and review efficiency in the local ambulatory ECG population, including AF false-positive burden, ventricular ectopy, pacemaker cases, pediatric or adult eligibility, technician edit time, physician overread quality, and downstream follow-up. |
Best governed as clinician-reviewed ECG interpretation support with defined technician queues, cardiologist overread, advisory-output labeling, report signoff, escalation rules, QA sampling, and conventional review fallback. |
| Tempus |
Separate molecular assays, companion-diagnostic claims, EHR assistants, imaging algorithms, trial matching, and care-pathway notifications because each workflow can carry different regulatory and clinical accountability. |
Review whether data is handled under website privacy, notice-of-privacy-practices, customer contract, research agreement, or de-identified data program before connecting EHR, genomic, imaging, or real-world datasets. |
Require product-level validation for the disease area, data type, model output, and care setting rather than relying on broad precision-medicine platform positioning. |
Map how outputs enter tumor boards, EHR workflows, trial screening, imaging review, care-gap closure, or life-sciences analysis, and define who approves downstream actions. |
| Tempus One |
Treat as high-risk precision-medicine decision support and workflow automation; separate clinical reference, documentation, prior authorization, trial matching, cohort research, and order-related use because each can carry different regulatory, contractual, and clinician-accountability obligations. |
Review Tempus privacy and compliance terms, customer agreements, EHR integration scope, PHI flows, support access, retention, audit logging, cross-product data use, and whether custom agents can access institution-specific procedures or repositories. |
Validate every guideline, biomarker, trial, patient-history, and cohort output against the underlying Tempus report, EHR note, guideline source, source excerpt, or research dataset before relying on it clinically. |
Best governed as clinician- or researcher-reviewed assistive infrastructure with local rules for source checking, note editing, prior-authorization review, trial-screening confirmation, patient communication, and custom-agent change control. |
| SOPHiA GENETICS |
Confirm the exact SOPHiA DDM module, Dx-mode status, IVDR claim, local lab validation path, and whether the workflow is diagnostic, research, or exploratory before clinical use. |
Review data-protection flyers, hosting model, anonymization, sample control, cross-institution insight sharing, HIPAA/GDPR commitments, and the customer agreement for genomic or imaging data. |
Validate the assay, scanner, sequencing, and module performance against the lab's specimen type, disease area, population, and local quality-management requirements. |
Map sample preparation, sequencing or imaging, data upload, interpretation, LIMS/EHR transfer, clinician review, and exception handling before relying on outputs. |
| Guardant InfinityAI |
Separate exploratory cohort analytics, biomarker discovery, testing-value analysis, and any patient-specific use because each can carry different clinical, regulatory, or submission expectations. |
Review consent, de-identification, data-use agreements, partner access, longitudinal clinical-genomic linkage, and any customer-data upload before using oncology datasets. |
Check data provenance, completeness, cohort definitions, molecular-pattern methods, external validation, and whether insights are hypotheses, real-world evidence, or clinically actionable findings. |
Use with oncology, bioinformatics, regulatory, privacy, and commercial review paths before applying outputs to trials, testing strategy, or patient-care workflows. |
| ArteraAI Prostate |
Verify the exact ArteraAI Prostate version and indication against FDA De Novo DEN240068, CLIA/CAP lab status, scanner compatibility, NCCN-referenced use, CE/IVDR status, and partner-specific implementations before clinical use. |
Review the HIPAA notice, privacy policy, ordering workflow, lab data handling, de-identification, retention, report access, and payer or partner data flows because the test uses pathology images and clinical information. |
Check validation cohorts, Phase 3 trial evidence, population representation, endpoint definitions, scanner or specimen constraints, and whether the report output supports the intended decision in the local tumor board workflow. |
Use as a clinician-ordered precision-oncology input with urology, radiation oncology, pathology, and patient shared-decision review before treatment intensification, active surveillance, salvage therapy, or metastatic prostate workflows are changed. |
| Avenda Unfold AI |
Treat as regulated radiological computer-assisted diagnostic software and match use to K221624 labeling, trained physician use, prostate oncological workflow scope, and any reimbursement-specific requirements. |
Review MRI, biopsy, pathology, PSA, report, and provider-ordering data flows along with privacy-policy terms, BAA coverage, support access, retention, and whether patient data is used for analytics or product improvement. |
Inspect validation evidence for cancer extent mapping, encapsulation confidence, focal therapy planning, MRI-visible and MRI-invisible disease, and performance across local scanners, biopsy approaches, and patient populations. |
Best governed as physician-reviewed prostate cancer decision support with documented image review, biopsy/pathology reconciliation, treatment-planning discussion, patient shared decision-making, and outcomes monitoring. |
| Unlearn |
Treat as clinical trial methodology and evidence-generation infrastructure that needs protocol, SAP, ethics, sponsor, and regulator review before affecting enrollment or analysis. |
Review trial-participant data flows, baseline-variable scope, consent, de-identification, retention, transfers, automated-decision disclosures, and sponsor agreements. |
Inspect disease-model validation, calibration, external generalizability, uncertainty intervals, bias testing, and whether assumptions match the endpoint and population. |
Best used with biostatistical governance where digital-twin outputs are versioned, auditable, and reconciled with trial operations and regulatory commitments. |
| Owkin K Pro |
Treat K Pro as biomedical research and drug-development support unless a deployment links outputs to patient-specific care or regulated-development decisions that need formal controls. |
Confirm whether data enters Owkin K, a customer environment, or the patient-data network, then review GDPR, ISO, data-transfer, de-identification, and access-control terms. |
Require visible source data, reproducible methods, statistical assumptions, uncertainty, and expert review for target, biomarker, subgroup, or report-generation claims. |
Best used inside governed R&D workflows where domain scientists review generated analyses before they influence experiments, trial design, or translational strategy. |
| Caris Life Sciences |
Review the selected assay, laboratory status, report language, AI signature, and molecular tumor board use separately instead of treating Caris as one uniform AI product. |
Confirm patient consent, molecular-data handling, data-use permissions, portal access, retention, and whether research, biopharma, or clinical workflows have different terms. |
Check the biomarker, signature, and treatment-association evidence for the cancer type and report context before using outputs in clinical recommendations. |
Route AI insights through oncologist, molecular pathology, genetic counseling, payer, and tumor board review as appropriate for the test and patient context. |
| Flatiron Assist |
Treat as high-governance oncology clinical decision support; verify how pathways, NCCN content, local preferences, biomarkers, and prior-authorization workflows affect clinical accountability. |
Review EHR integration, user permissions, patient-data exchange, reporting exports, pathway analytics, and contractual PHI terms before enabling point-of-care use. |
Validate guideline currency, custom pathway governance, biomarker fit, trial matching, concordance reporting, and denial impact against local oncology practice. |
Best governed through oncology pathway committees, EHR build review, clinician override tracking, prior-authorization monitoring, and periodic pathway updates. |
| Truveta |
Treat Truveta as research, analytics, and evidence infrastructure, not clinical decision software, unless a deployment changes patient care or supports a regulated submission that needs study-specific controls. |
Review de-identification, data-use agreements, linked-data scope, trusted research environment controls, HITRUST/SOC/ISO materials, and whether any customer-provided data changes obligations. |
Validate cohort definitions, code sets, source traces, assumptions, missingness, confounding, and reproducibility artifacts before using outputs for regulatory, clinical, or commercial decisions. |
Best used with defined research protocols, analyst review, versioned methods, and governed export paths rather than ad hoc natural-language answers. |
| Deep 6 AI |
Treat as research operations and trial-matching infrastructure; confirm IRB, recruitment, consent, and clinical-trial obligations before using matches for patient contact. |
Review EHR data access, PHI handling, site agreements, role permissions, audit trails, data retention, and whether sponsor-facing workflows expose identifiable data. |
Validate extraction accuracy against local charts, especially for nuanced inclusion and exclusion criteria, temporality, biomarkers, medications, and comorbidities. |
Best used with study-team review loops where AI-ranked candidates are confirmed by trained staff before outreach, enrollment, or protocol decisions. |
| Dyania Health Synapsis |
Treat as research operations, chart review, and evidence infrastructure unless a deployment directly changes patient care; confirm IRB, protocol, registry, and sponsor obligations before use. |
Review BAA terms, EHR access, PHI handling, role permissions, audit trails, retention, and whether sponsor-facing workflows expose identifiable or re-identifiable records. |
Validate extraction and matching accuracy against local charts, especially for nuanced criteria, dates, negation, biomarkers, medications, disease status, and missing data. |
Best used with explicit human confirmation steps before trial outreach, registry submission, protocol decisions, or real-world evidence conclusions. |
| TriNetX |
Treat as clinical research, feasibility, and real-world evidence infrastructure unless a deployment directly affects patient care; align use with protocol, IRB, sponsor, and regional research rules. |
Review federation model, data rights, de-identification or pseudonymization, site-level patient re-identification workflow, audit logs, retention, and cross-border data controls. |
Validate cohort counts, criteria logic, ontology mappings, missing-data assumptions, site performance signals, and diversity metrics against known local or sponsor trial data. |
Best used as decision support for study teams, with documented human confirmation before protocol amendments, site selection, patient outreach, or RWE conclusions. |
| Medidata AI |
Treat as regulated clinical research infrastructure; protocol changes, external controls, synthetic data, and trial-risk actions need statistical, clinical, sponsor, and regulatory review. |
Review trial-data rights, RWD linkage, patient-level data handling, synthetic data controls, role permissions, auditability, retention, and trust documentation. |
Validate recommendations against the study protocol, therapeutic area, geography, enrollment history, endpoint definitions, safety signals, and statistical analysis plan. |
Best deployed inside formal clinical operations governance, with traceable human decisions before protocol optimization, site actions, data queries, or external comparator use. |
| ConcertAI |
Treat as oncology RWE, trial, and analytics infrastructure unless a specific workflow is used in patient care or a regulated submission; align each use with protocol, sponsor, IRB, and regulatory expectations. |
Review de-identification, data rights, oncology network agreements, biomarker data handling, customer-data uploads, role access, retention, and whether sponsor-facing outputs expose site or patient-level information. |
Validate cohort definitions, real-world data completeness, biomarker capture, model assumptions, source traceability, and study reproducibility before relying on outputs for evidence or trial decisions. |
Best used with oncology research, biostatistics, trial operations, privacy, and clinical governance so AI-generated insights are reviewed before trial, commercial, or quality programs change. |
| Aetion Evidence Platform |
Treat as evidence-generation infrastructure; regulatory, payer, safety, or HTA use needs protocol, data, methods, versioning, and review controls matched to the decision. |
Review data-source agreements, cloud deployment, de-identification, synthetic data generation, user permissions, audit exports, and whether linked or customer-provided data changes obligations. |
Check study design, cohort logic, outcome definitions, confounding control, sensitivity analyses, reproducibility, and whether AI-assisted steps are transparent enough for review. |
Best used by epidemiology, HEOR, safety, regulatory, and analytics teams with reusable study components and explicit signoff before evidence leaves the research workflow. |
| nference nSights |
Treat as research and evidence infrastructure unless outputs are linked to patient-specific care, diagnostics, or regulated submissions that require formal controls. |
Review de-identification, federated or licensed-data access, institution data rights, modality add-ons, exports, retention, and user permissions before using sensitive cohorts. |
Validate cohort logic, source-data completeness, AI curation methods, modality coverage, missingness, and reproducibility for the intended drug, diagnostic, or research question. |
Best used with clinical research, informatics, biostatistics, privacy, and domain-science review before insights feed experiments, publications, models, or development programs. |
| KidneyIntelX.dkd |
Treat as a regulated in vitro diagnostic and match deployment to the FDA De Novo intended use, ordering requirements, lab status, and any local diagnostic governance before clinical use. |
Review specimen handling, LIMS data flows, EHR integration, laboratory access, ISO/IEC 27001 scope, retention, payer data exchange, and BAA or covered-entity terms. |
Check FDA decision materials, validation population, biomarker and clinical-variable inputs, real-world performance, reimbursement evidence, and local outcome tracking before scaling. |
Best governed as a clinician-reviewed kidney-risk pathway where results trigger documented follow-up, medication or referral review, patient counseling, and post-deployment monitoring. |
| Swift Medical |
Treat as high-risk wound assessment and documentation support; verify intended use, jurisdiction, and whether local deployment claims make it clinical decision support or device software. |
Review PHI in wound images, mobile capture, cloud storage, consent, user permissions, audit logs, data retention, BAA terms, and model-improvement data use. |
Validate measurement consistency, tissue classification, healing predictions, documentation completeness, escalation accuracy, and subgroup performance in the intended care setting. |
Best deployed with wound-care protocols that define image capture standards, specialist review, escalation, reimbursement documentation, and ongoing quality monitoring. |
| Net Health Tissue Analytics |
Clarify whether the deployment is documentation support, measurement support, analytics, or clinical decision support, and verify any device or software claims for the intended setting. |
Review PHI in wound photos, mobile capture workflow, cloud processing, access controls, retention, EHR interfaces, audit logs, and BAA terms. |
Test measurement accuracy, tissue classification, pressure injury analytics, workflow time savings, and false reassurance risks against local wound-care standards. |
Best used with clinician-reviewed wound rounds, standardized photography, escalation rules, and documented ownership for updating the care plan. |
| eKare inSight |
Verify the exact inSight device and software status, intended use, wound types, and measurement claims for the country and care setting. |
Review wound image storage, telehealth access, mobile-device controls, patient identifiers, EHR export, BAA terms, and retention. |
Validate wound-area, depth, and tissue measurements against local standards and monitor variability by camera workflow, lighting, and anatomy. |
Best used with repeatable capture protocols, wound-specialist review, telehealth handoff rules, and documentation workflows that preserve an audit trail. |
| Healthy.io Minuteful for Wound |
Verify FDA registration or local device status, country availability, intended use, and whether the workflow is measurement support, documentation, or decision support. |
Review mobile capture, image upload, remote consultation access, consent, identity controls, retention, BAA terms, and patient-facing communication. |
Validate smartphone wound measurements, tissue assessment, remote-review reliability, adherence, equity, and follow-up outcomes in the care model being used. |
Best deployed with staff training, calibration supplies, remote expert coverage, escalation thresholds, and documentation rules for longitudinal wound monitoring. |
| MolecuLight |
Match the device model and intended use to FDA-cleared indications and avoid treating fluorescence as a standalone infection diagnosis. |
Review image transfer, Wi-Fi, local device storage, EHR integration, HIPAA/SOC 2 materials, user controls, and retention. |
Assess clinical studies, detection limitations, false negatives from blood or workflow issues, impact on antimicrobial use, and local wound-care outcomes. |
Best used as adjunctive imaging during wound assessment with training, room setup, interpretation rules, documentation, and escalation pathways. |
| Spectral AI DeepView |
Treat as regulated medical-device software and match use to the FDA De Novo indication, labeling, trained users, and burn-care setting. |
Review imaging data flow, device connectivity, support access, storage, retention, BAA terms, and whether research or commercial deployments use different data terms. |
Review pivotal and post-market evidence for healing prediction, false reassurance risk, timing after injury, skin tone, burn depth, and effect on grafting decisions. |
Best governed as burn-specialist decision support with documented imaging timing, interpretation, escalation, treatment planning, and outcome monitoring. |
| ModelOp Center |
Use for governance orchestration, not as proof that a model is safe or cleared; still map each AI system to intended use, medical-device status, payer policy, privacy law, and local review board requirements. |
Review PHI exposure in model inventories, validation datasets, monitoring telemetry, evidence uploads, user comments, audit exports, integrations, retention, and BAA or data-processing terms. |
Check whether validation evidence, model-change records, monitoring thresholds, fairness tests, and incident reviews are complete enough for high-risk clinical or payer workflows. |
Best deployed as the central AI governance register and approval workflow for health systems or life-sciences teams, with named clinical, compliance, security, and model-owner responsibilities. |
| Credo AI Platform |
Use to organize governance controls and evidence, while separately verifying medical-device status, health-data law, institutional review, and clinical-safety requirements for each AI system. |
Review whether PHI, prompts, system cards, vendor evidence, control results, and audit exports are stored in Credo AI and how access, retention, and integrations are governed. |
Confirm the registry and policy mapping capture validation evidence, monitoring results, human oversight, bias checks, incident review, and retirement decisions for high-risk systems. |
Best governed as an enterprise intake and control layer for AI systems, with healthcare-specific review gates before clinical, payer, or patient-facing deployment. |
| Mendel Redact |
Treat as privacy and data-governance infrastructure, not proof that a dataset is legally de-identified; confirm HIPAA, expert-determination, IRB, contractual, state, and cross-border obligations for each data use. |
Review original document ingestion, PHI masking categories, redacted file outputs, JSON coordinates, audit trails, user access, support access, retention, hosting, BAAs, DPAs, and downstream data-sharing agreements. |
Validate sensitivity, false negatives, over-redaction, clinical-context preservation, OCR performance, and re-identification risk on local document types before using outputs for research or commercial analytics. |
Best governed as a privacy-review step inside a clinical-data pipeline, with quality sampling, exception queues, expert review, approval gates, and documentation before data export or reuse. |
| Fiddler AI Observability |
Treat as monitoring and risk-control infrastructure, not a substitute for regulated-device validation or clinical-governance approval of the underlying AI system. |
Review trace capture, prompt and output logging, PHI detection, redaction, retention, access controls, integrations, and BAA or enterprise security terms. |
Validate that metrics detect the failure modes that matter locally, including drift, missing context, hallucination, inequitable performance, unsafe agent actions, and alert fatigue. |
Best used after AI deployment with incident queues, monitoring owners, risk thresholds, retraining/change control, and documented escalation paths. |
| Arize AI Observability |
Use as technical monitoring and evaluation infrastructure while separately documenting intended use, clinical validation, regulatory status, and governance approval for the AI application itself. |
Review telemetry design, PHI handling, redaction, hosted versus self-managed deployment, retention, user access, audit trails, and BAA/security documentation. |
Require task-specific eval sets, clinician-reviewed labels, drift checks, regression gates, and outcome monitoring before using observability dashboards as governance evidence. |
Best suited to teams that can instrument models and agents, maintain eval datasets, triage alerts, and feed findings into release and incident processes. |
| Monitaur |
Use to document governance and compliance controls, while separately verifying healthcare, payer, insurance, medical-device, and health-data obligations for the specific AI use case. |
Review claims or health-data ingestion, model telemetry, validation artifacts, user permissions, evidence exports, retention, subcontractors, and BAA or data-processing terms. |
Check that validation protocols and performance reports reflect real local populations, payer rules, fairness expectations, and post-deployment changes. |
Best used with model risk committees, compliance owners, technical model owners, and operational teams that act on validation and monitoring findings. |
| Saidot |
Use for EU-oriented AI governance workflow support while separately confirming medical-device, health-data, clinical, procurement, and national regulatory obligations for each AI system. |
Review how system records, evidence, health-data references, prompts, outputs, vendors, and audit materials are stored, accessed, retained, and exported. |
Confirm whether policy templates, inherited evidence, and risk suggestions are backed by system-specific validation, monitoring, human oversight, and incident evidence. |
Best suited to organizations that need a live AI inventory and cross-functional approval process spanning compliance, product, clinical, privacy, and technical teams. |
| Chryso.ai |
Use as governance and compliance evidence infrastructure; separately verify medical-device status, clinical validation, security review, and local approval for every AI system it tracks. |
Review whether PHI, staff records, prompts, outputs, telemetry, screenshots, audit artifacts, or vendor evidence are stored in the platform and under what BAA, access, retention, and export controls. |
Confirm that automated evidence packages reflect real validation, monitoring, fairness, incident, training, and policy-review activity rather than unchecked template completion. |
Best governed as a compliance operations layer for healthcare AI programs, with named owners for policy updates, training completion, evidence review, and monitored-agent incidents. |
| ALIGNMT AI |
Use as governance and monitoring infrastructure while separately classifying every AI system by intended use, medical-device status, HTI-1 or other transparency obligations, local policy, and clinical approval path. |
Review service agreements, BAA terms, patient-data handling, de-identified data claims, validation datasets, monitoring telemetry, third-party analytics, retention, access controls, and report-card publication rules. |
Require product-specific validation plans, subgroup or fairness results, benchmark provenance, real-world monitoring definitions, and documented remediation for identified risks. |
Best governed as a cross-functional oversight layer spanning clinical, legal, compliance, product, data science, and executive owners for AI intake, assessment, monitoring, and mitigation. |
| Risk Meridian |
Treat as governance documentation support; legal, compliance, and clinical owners still need to classify each AI use case, validate evidence, and approve disclosures or regulatory submissions. |
Check whether health data, vendor records, AI-system details, incidents, board reports, control evidence, and user activity are stored, exported, or shared, and whether healthcare contracts cover required safeguards. |
Verify that risk scores, controls, reports, and certifications are backed by actual validation, monitoring, incident, privacy, and human-review evidence instead of questionnaire completion alone. |
Best used to establish a repeatable AI intake, risk-review, control-tracking, incident, re-assessment, and board-reporting cadence for healthcare AI programs. |
| Censinet RiskOps AI Governance |
Treat as governance and risk-management infrastructure; each AI system still needs intended-use classification, FDA or local regulatory review, privacy/security assessment, and accountable clinical ownership. |
Review vendor-risk evidence, questionnaire answers, AI inventory details, clinical-function mappings, support access, benchmarking participation, retention, exports, and BAA or data-processing terms before loading sensitive data. |
Require that AI risk scores, NIST AI RMF mappings, AI governance assessments, benchmarking outputs, and recommended controls trace back to product-specific evidence and local validation. |
Best used as a cross-functional operating layer for AI intake, third-party review, enterprise-risk alignment, exception tracking, and ongoing committee reporting. |
| Trase OS |
Classify each agent by workflow, intended use, clinical impact, and human-review boundary; governed runtime controls do not by themselves establish medical-device status or clinical safety. |
Review deployment topology, EHR connections, PHI handling, prompt and output retention, audit trails, SDK integrations, support access, HIPAA documentation, SOC 2 scope, and customer security controls. |
Validate agent accuracy, escalation rates, failure handling, cost claims, productivity claims, and clinical-operation impact against local workflows before expanding beyond a narrow pilot. |
Best piloted with one bounded workflow, explicit policy gates, human review, service-line owners, and post-deployment monitoring before allowing agents to act across systems. |
| ShadowIQ for Healthcare |
Treat as an AI governance, enforcement, and evidence layer; each downstream clinical, payer, or SaaS AI use case still needs intended-use classification, HTI-1 or FDA SaMD review when applicable, and accountable human oversight. |
Review BAA availability, DPA terms, PHI detection limits, redaction or tokenization behavior, subprocessor/model routing, tenant keys, retention periods, evidence exports, and access controls. |
Validate claims about zero PHI egress, signed decision receipts, policy enforcement, registry completeness, and FDA lifecycle artifacts against a representative local workload before production use. |
Best governed as an AI traffic-control and audit-evidence layer with change control for policies, approved model routes, exception queues, incident review, and periodic governance committee reporting. |
| Harness.health |
Use to maintain oversight of AI tools, but still evaluate each product's intended use, FDA or local regulatory status, clinical validation, and institutional approval pathway. |
Review EHR integrations, safety-event records, metrics, contracts, vendor documentation, user accounts, audit logs, retention, and whether a BAA or equivalent agreement is required. |
Require local evidence that monitored metrics and safety-event workflows detect meaningful documentation, imaging, CDS, and access-tool issues rather than just deployment counts. |
Best deployed as a health-system governance registry and monitoring surface, with formal committee review, service-line owners, and safety-event feedback loops. |
| SAIGE |
Use as healthcare AI governance workflow support while separately classifying each AI system by intended use, medical-device status, privacy law, procurement terms, and clinical governance requirements. |
Review whether registry data, vendor submissions, risk assessments, validation artifacts, comments, and monitoring data include PHI or confidential security information. |
Confirm that risk scores and prioritization decisions are supported by system-specific validation, monitoring, bias, incident, and change-control evidence. |
Best suited to organizations standardizing AI intake, vendor evidence collection, risk review, policy alignment, and ongoing reassessment in one shared workflow. |
| Grid Health |
Treat as monitoring and governance infrastructure; separately classify every tracked AI tool by intended use, device status, clinical-risk tier, and local approval requirements. |
Review data connectors, read-only implementation claims, EHR or vendor telemetry, PHI exposure, role access, retention, audit trails, and BAA or security documentation. |
Confirm that drift, adoption, editing, cost, and utilization metrics are mapped to clinically meaningful thresholds and reviewed against original validation baselines. |
Best used by cross-functional AI governance teams that can start with one workflow, interpret monitoring signals, and decide whether to expand, retrain, restrict, or retire AI tools. |
| Asher Informatics |
Use as healthcare AI governance infrastructure while separately classifying each AI tool by intended use, FDA or local medical-device status, institutional policy, and state or federal AI requirements. |
Review DICOM, EHR, signal, text, policy, monitoring, and model-output integrations for PHI exposure, access control, hosting model, retention, BAA coverage, and audit exports. |
Confirm that monitoring metrics, utility modeling, and governance controls map to local validation baselines, real workflow outcomes, subgroup performance, and post-deployment change management. |
Best piloted with one high-value AI service line where governance, compliance, clinical, operational, and informatics owners can compare monitoring outputs with real-world performance. |
| Cognome ExplainerAI |
Use for governance evidence and model transparency while independently confirming FDA, HIPAA, medical-device, security, procurement, and institutional review requirements for each AI use case. |
Review cloud versus on-premise hosting, HL7/EHR feeds, endpoint scanning, public-LLM detection, PHI handling, access controls, retention, and business-associate terms. |
Require local validation that explanation, fairness, bias, drift, and outcome dashboards reflect clinically meaningful measures rather than generic model metrics. |
Best suited to mature analytics or informatics teams that can connect models, monitor real-world behavior, review alerts, and feed findings into formal AI governance workflows. |
| Caresyntax |
Classify each deployed Caresyntax module by intended use, jurisdiction, device status, analytics scope, and whether it influences intraoperative or post-operative clinical decisions. |
Review OR video, patient and staff identifiers, device data, cloud processing, regional hosting, retention, access logs, subcontractors, and BAA or data-processing agreement terms. |
Ask for procedure-specific validation, implementation references, performance metrics, safety-event review, and evidence that analytics improve the local surgical workflow being targeted. |
Best piloted with a defined surgical service line, governance owner, surgeon reviewers, and explicit rules for quality dashboards, coaching, and operational decisions. |
| Theator |
Confirm intended use for video analysis, documentation, quality improvement, and any clinical decision support before treating outputs as operational or care-affecting evidence. |
Review video capture, case linkage, user accounts, data retention, model-improvement rights, privacy notice terms, EHR integration, and access controls for surgical footage. |
Validate against local procedure types and surgeon-written documentation, tracking missed events, inaccurate steps, edit burden, coding impact, and inter-reviewer disagreement. |
Best used with surgeon signoff, quality-team review, and explicit limits around operative reports, training libraries, and performance dashboards. |
| Proximie |
Distinguish collaboration, training, workflow analytics, and any real-time surgical intelligence from regulated intraoperative guidance before deployment. |
Review patient and staff video, audio, data-region choices, cloud hosting, customer controller/processor roles, support access, retention, and customer agreements. |
Measure case delays, throughput, training value, remote-support quality, privacy incidents, staff workload, and whether AI insights are accurate for each service line. |
Best governed as connected-OR infrastructure with patient notice, credentialing rules, defined escalation paths, and review of every AI-derived operational recommendation. |
| Medtronic Touch Surgery ecosystem |
Confirm product labeling, country availability, intended use, and whether any analytics affect care, documentation, training, or credentialing decisions. |
Review Medtronic privacy terms, surgical video handling, patient identifiers, device metadata, hosting, retention, user access, and customer agreement requirements. |
Pilot with representative procedure videos and track capture quality, analytic accuracy, educator acceptance, surgeon edit burden, and training or quality-improvement outcomes. |
Best used with explicit postoperative review and education workflows, not as a substitute for surgeon judgment or local credentialing governance. |
| Moon Surgical Maestro |
Verify exact cleared indications, software version, ScoPilot status, procedure scope, geography, and hospital medical-device governance before clinical use. |
Review security, device telemetry, intraoperative data, analytics, cloud or edge processing, retention, support access, and privacy-notice terms. |
Assess local procedure times, setup burden, conversion risk, surgeon ergonomics, safety events, and whether insights improve outcomes or workflow without introducing distraction. |
Best governed like a surgical device plus AI-enabled workflow: credentialing, training, emergency fallback, surgeon control, and biomedical engineering oversight are central. |
| Activ Surgical ActivSight |
Confirm product labeling, clearance, country availability, compatible use cases, and whether AI-enabled modes are investigational or cleared for the planned workflow. |
Review device data, video, image capture, support access, retention, security, and whether case data leaves the OR or hospital environment. |
Pilot under surgeon oversight and track visualization accuracy, missed findings, false positives, setup burden, adverse events, and whether outputs change decisions safely. |
Best evaluated as intraoperative adjunctive visualization with explicit surgeon control, training, failure-mode planning, and procedure-specific governance. |
| Apella |
Treat as perioperative operations and documentation intelligence unless a deployment uses predictions or event detection to drive care decisions; review medical-device, safety, and institutional governance boundaries for each workflow. |
Map ceiling cameras, live video, patient privacy blurring, staff images, event timelines, SMS notifications, Epic write-back, historical video review, retention, access controls, and support access before room installation. |
Validate event detection, predicted delays, case-duration forecasts, staffing recommendations, and utilization metrics against local OR data, procedure types, and staffing practices. |
Best governed as an OR operations layer with named owners for event correction, schedule decisions, staffing escalation, privacy review, and post-deployment performance monitoring. |
| Surgical Safety Technologies OR Black Box |
Separate quality improvement, education, risk management, analytics, and any care-affecting use because the platform's governance obligations change when outputs influence clinicians or credentialing. |
Review de-identification, audio and video capture, patient and staff images, clinical-environment data, retention, quality-review protections, access logs, and contractual data-use terms before installation. |
Require local validation that captured events, analytics, and trend reports reflect meaningful safety and efficiency signals rather than artifacts of procedure mix or camera placement. |
Best piloted with a formal safety culture plan, surgeon and staff communication, protected review process, incident escalation rules, and limits on punitive or unsupported use. |
| Cydar Maps |
Verify the exact product name, software version, indications, FDA or local authorization, and instructions for use before clinical deployment, especially for expanded vascular procedure coverage. |
Review CT and fluoroscopy data flow, cloud hosting, live collaboration, support access, authentication, retention, image sharing, and hospital data-processing terms. |
Validate planning measurements, map registration, overlay accuracy, radiation and contrast claims, procedure time effects, and post-operative assessment against local endovascular cases. |
Best governed as image-guided surgery support with surgeon confirmation, standard-imaging fallback, biomedical engineering involvement, and post-case review of guidance accuracy. |
| Asensus Intelligent Surgical Unit |
Confirm authorization, labeling, intended use, software version, geography, and enabled features because robotic-surgery systems require device governance and procedure-specific credentialing. |
Review procedure-data capture, video, telemetry, analytics, service access, cybersecurity controls, retention, and whether data leaves the hospital or device environment. |
Assess setup burden, camera-control accuracy, surgeon ergonomics, visual-guidance reliability, conversion planning, adverse events, and procedure-specific outcomes during local adoption. |
Best evaluated as a surgeon-controlled robotic surgery adjunct with formal training, biomedical engineering oversight, fallback procedures, and post-deployment device monitoring. |
| Proprio Paradigm |
Confirm the exact Paradigm System 510(k), software version, indications, geography, instrument compatibility, and training requirements before clinical use because this is high-risk surgical navigation. |
Review OR video and sensor capture, CT image handling, system logs, structured case data, support access, retention, cloud or local processing, cybersecurity controls, and customer privacy terms. |
Validate registration accuracy, instrument placement guidance, alignment measurements, radiation and workflow claims, adverse-event handling, and procedure-specific outcomes against local spine cases. |
Best governed as surgeon-controlled spinal navigation with biomedical engineering oversight, credentialing, standard-navigation fallback, post-case discrepancy review, and device performance monitoring. |
| PathKeeper System |
Treat as high-risk surgical navigation and verify K222355, software version, labeling, geography, procedure eligibility, accessory setup, and hospital medical-device governance before clinical use. |
Review preoperative CT handling, optical 3D images, workstation data transfer, system logs, support access, cybersecurity controls, retention, website/contact-data terms, and whether any case data leaves the hospital environment. |
Validate registration, instrument-tracking accuracy, setup burden, radiation-reduction claims, screw-placement workflow, false reassurance risk, and discrepancy handling against local spine cases before wider rollout. |
Best governed as surgeon-controlled spine navigation with biomedical engineering oversight, trained setup staff, registration confirmation, standard-imaging fallback, and post-deployment monitoring of accuracy and workflow impact. |
| ZEISS Surgery Optimizer |
Treat as surgical video review and education support unless local labeling or use changes; confirm non-medical-device status, country availability, compatible systems, and intended-use limits before using outputs in quality programs. |
Review surgical-video upload, patient and biometry data, ZEISS Health Data Platform terms, Microsoft cloud relationship, mobile access, retention, account roles, and cross-border data handling. |
Validate AI phase segmentation and KPI dashboards against local cataract cases, surgeons, equipment, and teaching objectives before relying on benchmark comparisons. |
Best governed as postoperative cataract video review with surgeon oversight, explicit teaching or quality-improvement boundaries, consent/notice review, and documented limits on performance interpretation. |
| SurgeryView.ai |
Treat as retrospective surgical video review, education, quality-improvement, or research support unless local use turns analytics into care, credentialing, or clinical decision support. |
Review the no-PHI upload rule, AI PII detection limits, user access, staff support access, video retention, public-posting warnings, institutional agreements, and whether consent or de-identification workflows are adequate. |
Validate phase segmentation, procedure support, benchmark relevance, and longitudinal metrics against local cases before using analytics for training or quality programs. |
Best piloted as a post-case review layer with surgeon approval, protected quality-review rules, explicit de-identification checks, and non-punitive use boundaries. |
| Stryker SurgiCount+ with Triton |
Treat as a high-risk medical-device software workflow and verify the exact cleared SurgiCount+ System software configuration, labeling, accessories, geography, indications, and hospital device-governance requirements before clinical use. |
Review device images, RFID sponge records, user-entered patient hemoglobin values, reports, EMR integration, cloud connectivity, offline behavior, access controls, retention, vendor support access, and customer security documentation. |
Validate blood-loss estimates, sponge-count reconciliation, missing-item alerts, charting accuracy, hemorrhage-response timing, false reassurance risk, staff workload, and protocol adherence with local OR and obstetric cases. |
Best implemented as an adjunct to established nursing, anesthesia, surgical, and obstetric hemorrhage workflows, with clear responsibility for confirming estimates, documenting discrepancies, and escalating patient-safety events. |
| Radformation AutoContour |
Treat as high-risk radiological image processing software for radiation therapy and verify the exact 510(k), version, modality, anatomy, region, and intended-use labeling before production use. |
Review image routing, DICOM metadata, support access, cloud or local processing, authentication, retention, audit logs, BAA terms, and whether patient data contributes to model updates. |
Commission site-by-site performance against local CT, MR, CBCT, scanner protocols, artifacts, abnormal anatomy, physician edits, plan dosimetry, and interobserver variation. |
Best governed as a planning accelerator with documented human review, contour editing, physicist/dosimetrist QA, fallback manual contouring, and monitoring for drift in edit burden. |
| MIM Contour ProtegeAI |
Confirm the exact FDA 510(k), product version, supported modality, structure set, intended use, and deployment geography because auto-segmentation claims vary by release. |
Review MIM workflow hosting, local or cloud deployment, DICOM and PHI handling, support access, retention, security controls, and contractual data-use language. |
Evaluate validation by anatomy and cancer site, local scanner performance, contour edit time, false contour risk, plan-quality effects, and physician acceptance. |
Best deployed with radiation oncologist review, dosimetry editing, physicist commissioning, structured exception handling, and documented fallback to manual contouring. |
| Siemens Healthineers DirectORGANS |
Verify region-specific authorization, supported CT simulator, software version, cancer site, and instructions for use because embedded simulation workflows may differ by market. |
Review CT simulator data flow, DICOM export, on-premises versus connected service processing, support access, logs, retention, and cybersecurity documentation. |
Commission by cancer site, scanner protocol, artifacts, contrast, anatomy, edit burden, physician acceptance, and downstream treatment-planning quality before relying on time-savings claims. |
Best used as CT-simulation workflow support with radiation oncologist and dosimetrist review, clear edit accountability, and manual-contouring fallback for unsupported or poor-quality cases. |
| MVision Contour+ |
Treat as high-risk radiotherapy image-analysis software and verify the exact FDA record, version, CT/MR scope, anatomy, intended users, and real-time adaptive planning exclusions. |
Review cloud versus local deployment, DICOM transfer, pseudonymization, TLS encryption, support access, retention, BAA terms, and whether images or contours are reused for model development. |
Commission by cancer site, scanner, CT and MR protocol, contouring guideline, outlier anatomy, edit burden, and plan-quality impact before relying on vendor time-saving claims. |
Best governed as an initial contour-template generator with radiation oncologist review, dosimetrist editing, physicist QA, exception handling, and fallback manual contouring. |
| TheraPanacea Annotate |
Verify exact ART-Plan module, FDA or CE status, intended-use labeling, geography, supported structures, and whether tumor or adaptive modules carry separate authorization. |
Review GDPR and HIPAA claims, cloud processing, DICOM metadata, retention, support access, user permissions, audit logs, and contractual PHI protections before sending radiotherapy images. |
Commission site-specific segmentation quality, contour edit burden, interobserver variability, anatomy-specific performance, guideline fit, and downstream treatment-plan effects. |
Best used as supervised contouring support with radiation oncologist validation, dosimetry editing, physicist QA, batch-workflow monitoring, and manual fallback for unsupported cases. |
| Mirada DLCExpert |
Verify current regulatory status, software version, anatomy, modality, deployment geography, and whether older DLCExpert clearance or CE materials apply to the purchased configuration. |
Review image routing, remote-reporting deployment, support access, user permissions, retention, audit logs, and contractual data-processing terms for radiotherapy images and contours. |
Commission contour quality by anatomy and site, compare edit burden against local standards, review clinical-acceptability studies, and monitor downstream plan-quality impact. |
Best governed as a zero-click initial contouring workflow with physician and dosimetrist review, documented edits, physicist oversight, and manual fallback. |
| RayStation Deep Learning Segmentation |
Treat as high-risk radiation oncology treatment-planning software and verify the exact RayStation release, 510(k) or local authorization, enabled model, modality, anatomy, and market restriction before production use. |
Review RayStation deployment architecture, image and contour storage, support access, scripting, logs, connected services, retention, BAA or data-processing terms, and whether model updates use customer data. |
Commission DLS performance by cancer site, scanner, protocol, contouring guideline, physician edit burden, abnormal anatomy, artifacts, and treatment-plan impact rather than relying only on vendor time-savings claims. |
Best governed as an integrated contouring and planning accelerator with radiation oncologist review, dosimetrist editing, physicist QA, documented exceptions, and manual fallback for unsupported cases. |
| GE HealthCare Critical Care Suite |
Match the deployed module to the exact FDA 510(k), device version, patient population, view type, and notification or triage indication; do not generalize pneumothorax clearance to unsupported diagnosis, tube-position, pediatric, or non-chest workflows. |
Review on-device processing, DICOM routing, PACS flags, secondary-capture images, device logs, service access, retention, network segmentation, and any cloud or support data flows under the health system's GE contract. |
Use the FDA summary, GE materials, and local pilot data to check sensitivity, specificity, small-pneumothorax performance, ET tube measurement accuracy, false alerts, missed cases, and turnaround-time impact in the target sites. |
Best governed as radiologist-reviewed chest X-ray triage and acquisition-support software with clear rules for technologist notifications, worklist priority, secondary captures, downtime, and post-deployment quality monitoring. |
| Biobeat Cuffless Blood Pressure Monitoring |
Match each deployment to the exact FDA-cleared device, 510(k) number, measured parameter, intended setting, adult population, calibration requirement, and non-critical-care limitation before using outputs in care workflows. |
Review Biobeat's privacy policy and enterprise contract for device data, mobile app data, dashboard access, tokenization, controller versus processor roles, anonymized analytics, geolocation connectivity data, retention, support access, and cross-border transfer controls. |
Validate cuffless blood-pressure and physiologic-signal performance against the local patient population, calibration process, wear time, skin and motion artifacts, home connectivity, report quality, and escalation outcomes. |
Best governed as clinician-reviewed remote physiologic monitoring with clear onboarding, calibration, patient instructions, report review, escalation, device troubleshooting, downtime, and removal-from-monitoring criteria. |
| Pieces Technologies |
Treat as high-impact clinical workflow and documentation support unless a configured use case starts making patient-specific diagnostic, treatment, admission-status, or utilization decisions; review intended use, CDS policy, and local governance before production automation. |
Review EHR data flow, voice capture, generated notes, prompts, logs, AWS or other model subprocessors, support access, retention, BAA terms, de-identification, customer data rights, and whether operational analytics can be reused for model or product improvement. |
Use Pieces' public safety-review claims and customer metrics as starting points only; validate hallucination, omission, bias, note-quality, length-of-stay, documentation-timeliness, utilization-management, and clinician-workload results with local chart review. |
Best governed as clinician-reviewed inpatient automation with explicit chart-verification steps, source traceability, signoff rules, exception queues, downtime fallback, monitoring owners, and periodic review of generated-content safety metrics. |
| PreciseDx PreciseBreast |
Treat as high-risk oncology prognostic software or laboratory testing until the exact ordering pathway, laboratory status, FDA or local authorization, intended population, and report claims are confirmed. |
Review slide image transfer, clinicopathologic data fields, laboratory ordering, vendor privacy terms, business-associate or data-processing agreements, retention, support access, and whether de-identified data may be used for model improvement. |
Compare published analytical and external validation evidence with local breast cancer subtypes, specimen workflow, scanner diversity, follow-up horizon, recurrence endpoint, calibration, and incremental value over existing assays. |
Best governed as tumor-board decision support where pathologists and oncologists interpret the AI-derived risk score beside standard pathology, biomarkers, genomic tests, treatment guidelines, and patient-specific preferences. |
| Lunit SCOPE |
Separate every SCOPE module, version, geography, study purpose, and intended use before deployment; research-use-only language on SCOPE IO, GP, uIHC, and IHC Suite pages should not be treated as diagnostic authorization. |
Review whole-slide image transfer, platform integrations, support access, annotations, study metadata, product-service data, de-identified data handling, retention, international transfers, and customer-contract privacy terms. |
Use Lunit's publication library, module-specific validation materials, and local pilot data to test scanner mix, tissue and stain quality, cancer subtype, biomarker endpoint, reproducibility, pathologist agreement, and trial-readout impact. |
Best governed as a module-specific digital pathology and biopharma analysis workflow with pathologist, translational science, clinical-trial, privacy, and regulatory review before outputs inform patient selection or reports. |
| Validic Impact |
Treat Validic Impact as clinical operations infrastructure unless a deployment uses AI summaries, alerts, or device data to drive patient-specific triage; review intended use, device status, monitoring obligations, and local clinical decision-support policy before go-live. |
Review Validic privacy, security, BAA or data-processing terms, client controller responsibilities, device and app permissions, EHR writes, support access, de-identified analytics, retention, Data Privacy Framework claims, and cross-border transfer controls. |
Pilot with the target condition, device mix, patient population, EHR workflow, staffing model, alert thresholds, AI-summary review, and escalation protocol before relying on outcomes, risk-stratification, or workload claims. |
Best governed as EHR-embedded remote monitoring infrastructure where clinicians remain responsible for alert review, trend interpretation, outreach, documentation, escalation, downtime, and patient removal from monitoring. |